{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cannabis sativa", "cannabidiol", "cannabis", "neurological disorders", "tetrahydrocannabinol"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38891938", "DateCompleted": {"Year": "2024", "Month": "06", "Day": "19"}, "DateRevised": {"Year": "2024", "Month": "06", "Day": "20"}, "Article": {"Language": ["eng"], "ELocationID": ["5749", "10.3390/ijms25115749"], "ArticleDate": [{"Year": "2024", "Month": "05", "Day": "25"}], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "25", "Issue": "11", "PubDate": {"Year": "2024", "Month": "May", "Day": "25"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "The Use of Compounds Derived from <i>Cannabis sativa</i> in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders.", "Abstract": {"AbstractText": ["Neurological disorders present a wide range of symptoms and challenges in diagnosis and treatment. <i>Cannabis sativa</i>, with its diverse chemical composition, offers potential therapeutic benefits due to its anticonvulsive, analgesic, anti-inflammatory, and neuroprotective properties. Beyond cannabinoids, cannabis contains terpenes and polyphenols, which synergistically enhance its pharmacological effects. Various administration routes, including vaporization, oral ingestion, sublingual, and rectal, provide flexibility in treatment delivery. This review shows the therapeutic efficacy of cannabis in managing neurological disorders such as epilepsy, neurodegenerative diseases, neurodevelopmental disorders, psychiatric disorders, and painful pathologies. Drawing from surveys, patient studies, and clinical trials, it highlights the potential of cannabis in alleviating symptoms, slowing disease progression, and improving overall quality of life for patients. Understanding the diverse therapeutic mechanisms of cannabis can open up possibilities for using this plant for individual patient needs."]}, "AuthorList": [{"Identifier": ["0000-0001-5211-661X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland."}], "LastName": "Stasi\u0142owicz-Krzemie\u0144", "ForeName": "Anna", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland."}], "LastName": "Nogalska", "ForeName": "Wiktoria", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland."}], "LastName": "Maszewska", "ForeName": "Zofia", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland."}], "LastName": "Maleszka", "ForeName": "Mateusz", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland."}], "LastName": "Dobro\u0144", "ForeName": "Maria", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland."}], "LastName": "Szary", "ForeName": "Agnieszka", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland."}], "LastName": "K\u0119pa", "ForeName": "Aleksandra", "Initials": "A"}, {"Identifier": ["0000-0002-9800-9446"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Developmental Neurology, Poznan University of Medical Sciences, Przybyszewski 49, 60-355 Poznan, Poland."}], "LastName": "\u017barowski", "ForeName": "Marcin", "Initials": "M"}, {"Identifier": ["0000-0002-6166-9424"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Occupational Therapy, Poznan University of Medical Sciences, Swi\u0119cickiego 6, 61-847 Poznan, Poland."}, {"Identifier": [], "Affiliation": "Department of Rehabilitation, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland."}], "LastName": "Hojan", "ForeName": "Katarzyna", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rehabilitation, Centre of Postgraduate Medical Education, Konarskiego 13, 05-400 Otwock, Poland."}], "LastName": "Lukowicz", "ForeName": "Malgorzata", "Initials": "M"}, {"Identifier": ["0000-0003-0891-5419"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Phytochemistry, Institute of Natural Fibres and Medicinal Plants, Wojska Polskiego 71b, 60-630 Poznan, Poland."}], "LastName": "Cielecka-Piontek", "ForeName": "Judyta", "Initials": "J"}], "GrantList": [{"GrantID": "UMO-2021/41/N/NZ7/01125", "Agency": "National Science Center", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anticonvulsants"}, {"RegistryNumber": "0", "NameOfSubstance": "Cannabinoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Neuroprotective Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Analgesics"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Cannabis"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Neurodegenerative Diseases"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Epilepsy"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Mental Disorders"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Pain"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anticonvulsants"}, {"QualifierName": ["therapeutic use", "pharmacology"], "DescriptorName": "Cannabinoids"}, {"QualifierName": ["therapeutic use", "chemistry", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["therapeutic use", "pharmacology", "chemistry"], "DescriptorName": "Neuroprotective Agents"}, {"QualifierName": ["therapeutic use", "chemistry", "pharmacology"], "DescriptorName": "Analgesics"}], "CoiStatement": "The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Sarfo F.S., Akassi J., Badu E., Okorozo A., Ovbiagele B., Akpalu A. Profile of Neurological Disorders in an Adult Neurology Clinic in Kumasi, Ghana. eNeurologicalSci. 2016;3:69\u201374. doi: 10.1016/j.ensci.2016.03.003.", "ArticleIdList": ["10.1016/j.ensci.2016.03.003", "PMC4839267", "27110596"]}, {"Citation": "Carriba P., Lorenz\u00f3n N., Dierssen M. Neurodevelopmental Disorders: 2023 Update. Free Neuropathol. 2023;4:4\u20138. doi: 10.17879/freeneuropathology-2023-4701.", "ArticleIdList": ["10.17879/freeneuropathology-2023-4701", "PMC10280276", "37347033"]}, {"Citation": "Crary J.F. Neurodegeneration: 2023 Update. Free Neuropathol. 2023;4:4\u201313. doi: 10.17879/freeneuropathology-2023-4899.", "ArticleIdList": ["10.17879/freeneuropathology-2023-4899", "PMC10484115", "37694160"]}, {"Citation": "Lamptey R.N.L., Chaulagain B., Trivedi R., Gothwal A., Layek B., Singh J. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int. J. Mol. Sci. 2022;23:1851. doi: 10.3390/ijms23031851.", "ArticleIdList": ["10.3390/ijms23031851", "PMC8837071", "35163773"]}, {"Citation": "Taylor J.J., Williams N.R., George M.S. Beyond Neural Cubism: Promoting a Multidimensional View of Brain Disorders by Enhancing the Integration of Neurology and Psychiatry in Education. Acad. Med. 2015;90:581\u2013586. doi: 10.1097/ACM.0000000000000530.", "ArticleIdList": ["10.1097/ACM.0000000000000530", "PMC4405399", "25340364"]}, {"Citation": "Carreira-M\u00edguez M., Navarro-Jim\u00e9nez E., Clemente-Su\u00e1rez V.J. Behavioral Patterns of Depression Patients and Control Population. Int. J. Environ. Res. Public Health. 2022;19:9506. doi: 10.3390/ijerph19159506.", "ArticleIdList": ["10.3390/ijerph19159506", "PMC9368084", "35954861"]}, {"Citation": "Szuhany K.L., Simon N.M. Anxiety Disorders: A Review. JAMA. 2022;328:2431\u20132445. doi: 10.1001/jama.2022.22744.", "ArticleIdList": ["10.1001/jama.2022.22744", "36573969"]}, {"Citation": "Mansour M., Joseph G.R., Joy G.K., Khanal S., Dasireddy R.R., Menon A., Barrie Mason I., Kataria J., Patel T., Modi S. Post-Traumatic Stress Disorder: A Narrative Review of Pharmacological and Psychotherapeutic Interventions. Cureus. 2023;15:e44905. doi: 10.7759/cureus.44905.", "ArticleIdList": ["10.7759/cureus.44905", "PMC10560516", "37814755"]}, {"Citation": "Williams O.C., Prasad S., McCrary A., Jordan E., Sachdeva V., Deva S., Kumar H., Mehta J., Neupane P., Gupta A. Adult Attention Deficit Hyperactivity Disorder: A Comprehensive Review. Ann. Med. Surg. 2023;85:1802\u20131810. doi: 10.1097/MS9.0000000000000631.", "ArticleIdList": ["10.1097/MS9.0000000000000631", "PMC10205222", "37228994"]}, {"Citation": "Doernberg E., Hollander E. Neurodevelopmental Disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11. CNS Spectr. 2016;21:295\u2013299. doi: 10.1017/S1092852916000262.", "ArticleIdList": ["10.1017/S1092852916000262", "27364515"]}, {"Citation": "Dan O. Recognition of Emotional Facial Expressions in Adolescents with Attention Deficit/Hyperactivity Disorder. J. Adolesc. 2020;82:1\u201310. doi: 10.1016/j.adolescence.2020.04.010.", "ArticleIdList": ["10.1016/j.adolescence.2020.04.010", "32442797"]}, {"Citation": "Salari N., Ghasemi H., Abdoli N., Rahmani A., Shiri M.H., Hashemian A.H., Akbari H., Mohammadi M. The Global Prevalence of ADHD in Children and Adolescents: A Systematic Review and Meta-Analysis. Ital. J. Pediatr. 2023;49:48. doi: 10.1186/s13052-023-01456-1.", "ArticleIdList": ["10.1186/s13052-023-01456-1", "PMC10120242", "37081447"]}, {"Citation": "Shaw P., Eckstrand K., Sharp W., Blumenthal J., Lerch J.P., Greenstein D., Clasen L., Evans A., Giedd J., Rapoport J.L. Attention-Deficit/Hyperactivity Disorder Is Characterized by a Delay in Cortical Maturation. Proc. Natl. Acad. Sci. USA. 2007;104:19649\u201319654. doi: 10.1073/pnas.0707741104.", "ArticleIdList": ["10.1073/pnas.0707741104", "PMC2148343", "18024590"]}, {"Citation": "Ho R.C., Zhang M.W., Tsang T.Y., Toh A.H., Pan F., Lu Y., Cheng C., Yip P.S., Lam L.T., Lai C.-M., et al. The Association between Internet Addiction and Psychiatric Co-Morbidity: A Meta-Analysis. BMC Psychiatry. 2014;14:183. doi: 10.1186/1471-244X-14-183.", "ArticleIdList": ["10.1186/1471-244X-14-183", "PMC4082374", "24947851"]}, {"Citation": "Jernel\u00f6v S., Larsson Y., Llenas M., Nasri B., Kaldo V. Effects and Clinical Feasibility of a Behavioral Treatment for Sleep Problems in Adult Attention Deficit Hyperactivity Disorder (ADHD): A Pragmatic within-Group Pilot Evaluation. BMC Psychiatry. 2019;19:226. doi: 10.1186/s12888-019-2216-2.", "ArticleIdList": ["10.1186/s12888-019-2216-2", "PMC6657040", "31340804"]}, {"Citation": "Elsabbagh M., Divan G., Koh Y.-J., Kim Y.S., Kauchali S., Marc\u00edn C., Montiel-Nava C., Patel V., Paula C.S., Wang C., et al. Global Prevalence of Autism and Other Pervasive Developmental Disorders. Autism Res. 2012;5:160\u2013179. doi: 10.1002/aur.239.", "ArticleIdList": ["10.1002/aur.239", "PMC3763210", "22495912"]}, {"Citation": "Grove J., Ripke S., Als T.D., Mattheisen M., Walters R.K., Won H., Pallesen J., Agerbo E., Andreassen O.A., Anney R., et al. Identification of Common Genetic Risk Variants for Autism Spectrum Disorder. Nat. Genet. 2019;51:431\u2013444. doi: 10.1038/s41588-019-0344-8.", "ArticleIdList": ["10.1038/s41588-019-0344-8", "PMC6454898", "30804558"]}, {"Citation": "Pringsheim T., Edwards M. Functional Movement Disorders. Neurol. Clin. Pract. 2017;7:141\u2013147. doi: 10.1212/CPJ.0000000000000350.", "ArticleIdList": ["10.1212/CPJ.0000000000000350", "PMC5669411", "29185540"]}, {"Citation": "Serranov\u00e1 T., Di Vico I., Tinazzi M. Functional Movement Disorder: Assessment and Treatment. Neurol. Clin. 2023;41:583\u2013603. doi: 10.1016/j.ncl.2023.02.002.", "ArticleIdList": ["10.1016/j.ncl.2023.02.002", "37775192"]}, {"Citation": "W\u00f3jcik-Grudzie\u0144 J., Rozenbajgier M., Ozga-Stachurska A., Paw\u0142owska P. Tourette Syndrom\u2014A Review of Current Literature. J. Educ. Health Sport. 2022;12:607\u2013613. doi: 10.12775/JEHS.2022.12.09.073.", "ArticleIdList": ["10.12775/JEHS.2022.12.09.073"]}, {"Citation": "CDC Data and Statistics on Tourette Syndrome|CDC.  [(accessed on 17 April 2024)]; Available online:  https://www.cdc.gov/ncbddd/tourette/data.html."}, {"Citation": "Dong B., Xu R., Lim M. The Pathophysiology of Trigeminal Neuralgia: A Molecular Review. J. Neurosurg. 2023;139:1471\u20131479. doi: 10.3171/2023.2.JNS23274.", "ArticleIdList": ["10.3171/2023.2.JNS23274", "37922556"]}, {"Citation": "Hamdan A., Galvez R., Katati M. Shedding Light on Neuropathic Pain: Current and Emerging Tools for Diagnosis, Screening, and Quantification. SAGE Open Med. 2024;12:20503121231218985. doi: 10.1177/20503121231218985.", "ArticleIdList": ["10.1177/20503121231218985", "PMC10858674", "38343869"]}, {"Citation": "Rugnath R., Orzechowicz C., Newell C., Carullo V., Rugnath A. A Literature Review: The Mechanisms and Treatment of Neuropathic Pain\u2014A Brief Discussion. Biomedicines. 2024;12:204. doi: 10.3390/biomedicines12010204.", "ArticleIdList": ["10.3390/biomedicines12010204", "PMC10812949", "38255308"]}, {"Citation": "Doneddu P.E., Pensato U., Iorfida A., Alberti C., Nobile-Orazio E., Fabbri A., Voza A. Neuropathic Pain in the Emergency Setting: Diagnosis and Management. J. Clin. Med. 2023;12:6028. doi: 10.3390/jcm12186028.", "ArticleIdList": ["10.3390/jcm12186028", "PMC10531819", "37762968"]}, {"Citation": "Epilepsy.  [(accessed on 26 February 2024)].  Available online:  https://www.who.int/news-room/fact-sheets/detail/epilepsy."}, {"Citation": "Anwar H., Khan Q.U., Nadeem N., Pervaiz I., Ali M., Cheema F.F. Epileptic Seizures. Discoveries. 2020;8:e110. doi: 10.15190/d.2020.7.", "ArticleIdList": ["10.15190/d.2020.7", "PMC7305811", "32577498"]}, {"Citation": "Scheffer I.E., Berkovic S., Capovilla G., Connolly M.B., French J., Guilhoto L., Hirsch E., Jain S., Mathern G.W., Mosh\u00e9 S.L., et al. ILAE Classification of the Epilepsies: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512\u2013521. doi: 10.1111/epi.13709.", "ArticleIdList": ["10.1111/epi.13709", "PMC5386840", "28276062"]}, {"Citation": "Ighodaro E.T., Maini K., Arya K., Sharma S. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2024. Focal Onset Seizure.", "ArticleIdList": ["29763181"]}, {"Citation": "Sarmast S.T., Abdullahi A.M., Jahan N. Current Classification of Seizures and Epilepsies: Scope, Limitations and Recommendations for Future Action. Cureus. 2020;12:e10549. doi: 10.7759/cureus.10549.", "ArticleIdList": ["10.7759/cureus.10549", "PMC7575300", "33101797"]}, {"Citation": "Fisher R.S., Cross J.H., D\u2019Souza C., French J.A., Haut S.R., Higurashi N., Hirsch E., Jansen F.E., Lagae L., Mosh\u00e9 S.L., et al. Instruction Manual for the ILAE 2017 Operational Classification of Seizure Types. Epilepsia. 2017;58:531\u2013542. doi: 10.1111/epi.13671.", "ArticleIdList": ["10.1111/epi.13671", "28276064"]}, {"Citation": "Yeni K. Stigma and Psychosocial Problems in Patients with Epilepsy. Explor. Neurosci. 2023;2:251\u2013263. doi: 10.37349/en.2023.00026.", "ArticleIdList": ["10.37349/en.2023.00026"]}, {"Citation": "Aaberg K.M., Bakken I.J., Lossius M.I., Lund S\u00f8raas C., Tallur K.K., Stoltenberg C., Chin R., Sur\u00e9n P. Short-Term Seizure Outcomes in Childhood Epilepsy. Pediatrics. 2018;141:e20174016. doi: 10.1542/peds.2017-4016.", "ArticleIdList": ["10.1542/peds.2017-4016", "29789444"]}, {"Citation": "Schmidt D., L\u00f6scher W. Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms. Epilepsia. 2005;46:858\u2013877. doi: 10.1111/j.1528-1167.2005.54904.x.", "ArticleIdList": ["10.1111/j.1528-1167.2005.54904.x", "15946327"]}, {"Citation": "Teneralli R.E., Cepeda M.S., Kern D.M., Novak G.P. Individuals Who Develop Drug-Resistant Epilepsy within a Year after Initial Diagnosis Have Higher Burden of Mental and Physical Diseases One-Year Prior to Epilepsy Diagnosis as Compared to Those Whose Seizures Were Controlled during the Same Interval. Epilepsy Behav. 2021;123:108243. doi: 10.1016/j.yebeh.2021.108243.", "ArticleIdList": ["10.1016/j.yebeh.2021.108243", "34425326"]}, {"Citation": "Devinsky O., Cilio M.R., Cross H., Fernandez-Ruiz J., French J., Hill C., Katz R., Di Marzo V., Jutras-Aswad D., Notcutt W.G., et al. Cannabidiol: Pharmacology and Potential Therapeutic Role in Epilepsy and Other Neuropsychiatric Disorders. Epilepsia. 2014;55:791\u2013802. doi: 10.1111/epi.12631.", "ArticleIdList": ["10.1111/epi.12631", "PMC4707667", "24854329"]}, {"Citation": "Porter B.E., Jacobson C. Report of a Parent Survey of Cannabidiol-Enriched Cannabis Use in Pediatric Treatment-Resistant Epilepsy. Epilepsy Behav. 2013;29:574\u2013577. doi: 10.1016/j.yebeh.2013.08.037.", "ArticleIdList": ["10.1016/j.yebeh.2013.08.037", "PMC4157067", "24237632"]}, {"Citation": "Elliott J., DeJean D., Clifford T., Coyle D., Potter B.K., Skidmore B., Alexander C., Repetski A.E., Shukla V., McCoy B., et al. Cannabis-Based Products for Pediatric Epilepsy: A Systematic Review. Epilepsia. 2019;60:6\u201319. doi: 10.1111/epi.14608.", "ArticleIdList": ["10.1111/epi.14608", "30515765"]}, {"Citation": "Vy\u0161ata O., \u0164upa O., Proch\u00e1zka A., Dole\u017eal R., Cejnar P., Bhorkar A.M., Dost\u00e1l O., Vali\u0161 M. Classification of Ataxic Gait. Sensors. 2021;21:5576. doi: 10.3390/s21165576.", "ArticleIdList": ["10.3390/s21165576", "PMC8402252", "34451018"]}, {"Citation": "Al-Khazaleh A.K., Zhou X., Bhuyan D.J., M\u00fcnch G.W., Al-Dalabeeh E.A., Jaye K., Chang D. The Neurotherapeutic Arsenal in Cannabis Sativa: Insights into Anti-Neuroinflammatory and Neuroprotective Activity and Potential Entourage Effects. Molecules. 2024;29:410. doi: 10.3390/molecules29020410.", "ArticleIdList": ["10.3390/molecules29020410", "PMC10821245", "38257323"]}, {"Citation": "Aguiar A.F.L., Campos R.M.P., Isaac A.R., Paes-Colli Y., Carvalho V.M., Sampaio L.S., de Melo Reis R.A. Long-Term Treatment with Cannabidiol-Enriched Cannabis Extract Induces Synaptic Changes in the Adolescent Rat Hippocampus. Int. J. Mol. Sci. 2023;24:11775. doi: 10.3390/ijms241411775.", "ArticleIdList": ["10.3390/ijms241411775", "PMC10380262", "37511537"]}, {"Citation": "Hourfane S., Mechqoq H., Bekkali A.Y., Rocha J.M., El Aouad N. A Comprehensive Review on Cannabis Sativa Ethnobotany, Phytochemistry, Molecular Docking and Biological Activities. Plants. 2023;12:1245. doi: 10.3390/plants12061245.", "ArticleIdList": ["10.3390/plants12061245", "PMC10058143", "36986932"]}, {"Citation": "Radwan M.M., Chandra S., Gul S., ElSohly M.A. Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis. Molecules. 2021;26:2774. doi: 10.3390/molecules26092774.", "ArticleIdList": ["10.3390/molecules26092774", "PMC8125862", "34066753"]}, {"Citation": "Mangal N., Erridge S., Habib N., Sadanandam A., Reebye V., Sodergren M.H. Cannabinoids in the Landscape of Cancer. J. Cancer Res. Clin. Oncol. 2021;147:2507\u20132534. doi: 10.1007/s00432-021-03710-7.", "ArticleIdList": ["10.1007/s00432-021-03710-7", "PMC8310855", "34259916"]}, {"Citation": "Filer C.N. Acidic Cannabinoid Decarboxylation. Cannabis Cannabinoid Res. 2022;7:262\u2013273. doi: 10.1089/can.2021.0072.", "ArticleIdList": ["10.1089/can.2021.0072", "PMC9225410", "34550791"]}, {"Citation": "Kovalchuk O., Kovalchuk I. Cannabinoids as Anticancer Therapeutic Agents. Cell Cycle. 2020;19:961\u2013989. doi: 10.1080/15384101.2020.1742952.", "ArticleIdList": ["10.1080/15384101.2020.1742952", "PMC7217364", "32249682"]}, {"Citation": "Franco R., Rivas-Santisteban R., Reyes-Resina I., Casanovas M., P\u00e9rez-Olives C., Ferreiro-Vera C., Navarro G., S\u00e1nchez de Medina V., Nadal X. Pharmacological Potential of Varinic-, Minor-, and Acidic Phytocannabinoids. Pharmacol. Res. 2020;158:104801. doi: 10.1016/j.phrs.2020.104801.", "ArticleIdList": ["10.1016/j.phrs.2020.104801", "32416215"]}, {"Citation": "Walsh K.B., McKinney A.E., Holmes A.E. Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses. Front. Pharmacol. 2021;12:777804. doi: 10.3389/fphar.2021.777804.", "ArticleIdList": ["10.3389/fphar.2021.777804", "PMC8669157", "34916950"]}, {"Citation": "Fordjour E., Manful C.F., Sey A.A., Javed R., Pham T.H., Thomas R., Cheema M. Cannabis: A Multifaceted Plant with Endless Potentials. Front. Pharmacol. 2023;14:1200269. doi: 10.3389/fphar.2023.1200269.", "ArticleIdList": ["10.3389/fphar.2023.1200269", "PMC10308385", "37397476"]}, {"Citation": "Clarke K., Porter R., Facey P., Thoms-Rodriguez C. Chemical Composition and Biological Activities of Jamaican Cannabis Sativa Essential Oils as the Plant Matures. Flavour Fragr. J. 2023;38:144\u2013151. doi: 10.1002/ffj.3732.", "ArticleIdList": ["10.1002/ffj.3732"]}, {"Citation": "Ferber S.G., Namdar D., Hen-Shoval D., Eger G., Koltai H., Shoval G., Shbiro L., Weller A. The \u201cEntourage Effect\u201d: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. Curr. Neuropharmacol. 2020;18:87\u201396. doi: 10.2174/1570159X17666190903103923.", "ArticleIdList": ["10.2174/1570159X17666190903103923", "PMC7324885", "31481004"]}, {"Citation": "McDougall J.J., McKenna M.K. Anti-Inflammatory and Analgesic Properties of the Cannabis Terpene Myrcene in Rat Adjuvant Monoarthritis. Int. J. Mol. Sci. 2022;23:7891. doi: 10.3390/ijms23147891.", "ArticleIdList": ["10.3390/ijms23147891", "PMC9319952", "35887239"]}, {"Citation": "Booth J.K., Page J.E., Bohlmann J. Terpene Synthases from Cannabis Sativa. PLoS ONE. 2017;12:e0173911. doi: 10.1371/journal.pone.0173911.", "ArticleIdList": ["10.1371/journal.pone.0173911", "PMC5371325", "28355238"]}, {"Citation": "Isidore E., Karim H., Ioannou I. Extraction of Phenolic Compounds and Terpenes from Cannabis Sativa L. By-Products: From Conventional to Intensified Processes. Antioxidants. 2021;10:942. doi: 10.3390/antiox10060942.", "ArticleIdList": ["10.3390/antiox10060942", "PMC8230455", "34200871"]}, {"Citation": "Gon\u00e7alves E.C.D., Baldasso G.M., Bicca M.A., Paes R.S., Capasso R., Dutra R.C. Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant. Molecules. 2020;25:1567. doi: 10.3390/molecules25071567.", "ArticleIdList": ["10.3390/molecules25071567", "PMC7181184", "32235333"]}, {"Citation": "Bautista J.L., Yu S., Tian L. Flavonoids in Cannabis Sativa: Biosynthesis, Bioactivities, and Biotechnology. ACS Omega. 2021;6:5119\u20135123. doi: 10.1021/acsomega.1c00318.", "ArticleIdList": ["10.1021/acsomega.1c00318", "PMC7931196", "33681553"]}, {"Citation": "Erridge S., Mangal N., Salazar O., Pacchetti B., Sodergren M.H. Cannflavins\u2014From Plant to Patient: A Scoping Review. Fitoterapia. 2020;146:104712. doi: 10.1016/j.fitote.2020.104712.", "ArticleIdList": ["10.1016/j.fitote.2020.104712", "32858172"]}, {"Citation": "Abdel-Kader M.S., Radwan M.M., Metwaly A.M., Eissa I.H., Hazekamp A., Sohly M.A. Chemistry and Biological Activities of Cannflavins of the Cannabis Plant. Cannabis Cannabinoid Res. 2023;8:974\u2013985. doi: 10.1089/can.2023.0128.", "ArticleIdList": ["10.1089/can.2023.0128", "PMC10714118", "37756221"]}, {"Citation": "Tomko A.M., Whynot E.G., Dupr\u00e9 D.J. Anti-Cancer Properties of Cannflavin A and Potential Synergistic Effects with Gemcitabine, Cisplatin, and Cannabinoids in Bladder Cancer. J. Cannabis Res. 2022;4:41. doi: 10.1186/s42238-022-00151-y.", "ArticleIdList": ["10.1186/s42238-022-00151-y", "PMC9306207", "35869542"]}, {"Citation": "LaVigne J.E., Hecksel R., Keresztes A., Streicher J.M. Cannabis Sativa Terpenes Are Cannabimimetic and Selectively Enhance Cannabinoid Activity. Sci. Rep. 2021;11:8232. doi: 10.1038/s41598-021-87740-8.", "ArticleIdList": ["10.1038/s41598-021-87740-8", "PMC8050080", "33859287"]}, {"Citation": "Russo E.B. The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No \u201cStrain\u201d, No Gain. Front. Plant Sci. 2018;9:1969. doi: 10.3389/fpls.2018.01969.", "ArticleIdList": ["10.3389/fpls.2018.01969", "PMC6334252", "30687364"]}, {"Citation": "Chaiton M., Kundu A., Rueda S., Di Ciano P. Are Vaporizers a Lower-Risk Alternative to Smoking Cannabis? Can. J. Public Health. 2021;113:293\u2013296. doi: 10.17269/s41997-021-00565-w.", "ArticleIdList": ["10.17269/s41997-021-00565-w", "PMC8975973", "34448130"]}, {"Citation": "Moreno-Sanz G., Madiedo A., Lynskey M., Brown M.R.D. \u201cFlower Power\u201d: Controlled Inhalation of THC-Predominant Cannabis Flos Improves Health-Related Quality of Life and Symptoms of Chronic Pain and Anxiety in Eligible UK Patients. Biomedicines. 2022;10:2576. doi: 10.3390/biomedicines10102576.", "ArticleIdList": ["10.3390/biomedicines10102576", "PMC9599241", "36289837"]}, {"Citation": "Poyatos L., P\u00e9rez-Acevedo A.P., Papaseit E., P\u00e9rez-Ma\u00f1\u00e1 C., Martin S., Hladun O., Siles A., Torrens M., Busardo F.P., Farr\u00e9 M. Oral Administration of Cannabis and \u0394-9-Tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina. 2020;56:309. doi: 10.3390/medicina56060309.", "ArticleIdList": ["10.3390/medicina56060309", "PMC7353904", "32585912"]}, {"Citation": "Lunn S., Diaz P., O\u2019Hearn S., Cahill S.P., Blake A., Narine K., Dyck J.R.B. Human Pharmacokinetic Parameters of Orally Administered \u03949-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences. Cannabis Cannabinoid Res. 2019;4:255\u2013264. doi: 10.1089/can.2019.0037.", "ArticleIdList": ["10.1089/can.2019.0037", "PMC6922062", "31872060"]}, {"Citation": "Vandrey R., Herrmann E.S., Mitchell J.M., Bigelow G.E., Flegel R., LoDico C., Cone E.J. Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes. J. Anal. Toxicol. 2017;41:83\u201399. doi: 10.1093/jat/bkx012.", "ArticleIdList": ["10.1093/jat/bkx012", "PMC5890870", "28158482"]}, {"Citation": "Schlienz N., Spindle T., Cone E., Herrmann E., Bigelow G., Mitchell J., Flegel R., Lodico C., Vandrey R. Pharmacodynamic Dose Effects of Oral Cannabis Ingestion in Healthy Adults Who Infrequently Use Cannabis. Drug Alcohol Depend. 2020;211:107969. doi: 10.1016/j.drugalcdep.2020.107969.", "ArticleIdList": ["10.1016/j.drugalcdep.2020.107969", "PMC8221366", "32298998"]}, {"Citation": "Barrus D.G., Capogrossi K.L., Cates S.C., Gourdet C.K., Peiper N.C., Novak S.P., Lefever T.W., Wiley J.L. Tasty THC: Promises and Challenges of Cannabis Edibles. Volume 2016. RTI Press; Research Triangle Park, NC, USA: 2016. Methods Report.", "ArticleIdList": ["10.3768/rtipress.2016.op.0035.1611", "PMC5260817", "28127591"]}, {"Citation": "Casiraghi A., Roda G., Casagni E., Cristina C., Musazzi U.M., Franz\u00e8 S., Rocco P., Giuliani C., Fico G., Minghetti P., et al. Extraction Method and Analysis of Cannabinoids in Cannabis Olive Oil Preparations. Planta Med. 2018;84:242\u2013249. doi: 10.1055/s-0043-123074.", "ArticleIdList": ["10.1055/s-0043-123074", "29202510"]}, {"Citation": "Robinson D., Ritter S., Yassin M. Comparing Sublingual and Inhaled Cannabis Therapies for Low Back Pain: An Observational Open-Label Study. Rambam Maimonides Med. J. 2022;13:e0026. doi: 10.5041/RMMJ.10485.", "ArticleIdList": ["10.5041/RMMJ.10485", "PMC9622393", "36394500"]}, {"Citation": "Mahmoudinoodezh H., Telukutla S.R., Bhangu S.K., Bachari A., Cavalieri F., Mantri N. The Transdermal Delivery of Therapeutic Cannabinoids. Pharmaceutics. 2022;14:438. doi: 10.3390/pharmaceutics14020438.", "ArticleIdList": ["10.3390/pharmaceutics14020438", "PMC8876728", "35214170"]}, {"Citation": "Makhakhe L. Topical Cannabidiol (CBD) in Skin Pathology\u2014A Comprehensive Review and Prospects for New Therapeutic Opportunities. S. Afr. Fam. Pract. 2022;64:5493. doi: 10.4102/safp.v64i1.5493.", "ArticleIdList": ["10.4102/safp.v64i1.5493", "PMC9210160", "35695447"]}, {"Citation": "ElSohly M.A., Gul W., Walker L.A. Pharmacokinetics and Tolerability of \u03949-THC-Hemisuccinate in a Suppository Formulation as an Alternative to Capsules for the Systemic Delivery of \u03949-THC. Med. Cannabis Cannabinoids. 2018;1:44\u201353. doi: 10.1159/000489037.", "ArticleIdList": ["10.1159/000489037", "PMC8489354", "34676321"]}, {"Citation": "Brenneisen R., Egli A., Elsohly M., Henn V., Spiess Y. The Effect of Orally and Rectally Administered \u0394 9-Tetrahydrocannabinol on Spasticity: A Pilot Study with 2 Patients. Int. J. Clin. Pharmacol. Ther. 1996;34:446\u2013452.", "ArticleIdList": ["8897084"]}, {"Citation": "Dell D.D., Stein D.P. Exploring the Use of Medical Marijuana for Supportive Care of Oncology Patients. J. Adv. Pract. Oncol. 2021;12:188\u2013201. doi: 10.6004/jadpro.2021.12.2.6.", "ArticleIdList": ["10.6004/jadpro.2021.12.2.6", "PMC8017802", "34109050"]}, {"Citation": "Huestis M.A. Human Cannabinoid Pharmacokinetics. Chem. Biodivers. 2007;4:1770\u20131804. doi: 10.1002/cbdv.200790152.", "ArticleIdList": ["10.1002/cbdv.200790152", "PMC2689518", "17712819"]}, {"Citation": "Balachandran P., Elsohly M., Hill K.P. Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: A Comprehensive Review. J. Gen. Intern. Med. 2021;36:2074\u20132084. doi: 10.1007/s11606-020-06504-8.", "ArticleIdList": ["10.1007/s11606-020-06504-8", "PMC8298645", "33515191"]}, {"Citation": "Buchtova T., Lukac D., Skrott Z., Chroma K., Bartek J., Mistrik M. Drug\u2013Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics. Int. J. Mol. Sci. 2023;24:2885. doi: 10.3390/ijms24032885.", "ArticleIdList": ["10.3390/ijms24032885", "PMC9917508", "36769206"]}, {"Citation": "Chen S., Kim J.-K. The Role of Cannabidiol in Liver Disease: A Systemic Review. Int. J. Mol. Sci. 2024;25:2370. doi: 10.3390/ijms25042370.", "ArticleIdList": ["10.3390/ijms25042370", "PMC10888697", "38397045"]}, {"Citation": "Jadoon K.A., Ratcliffe S.H., Barrett D.A., Thomas E.L., Stott C., Bell J.D., O\u2019Sullivan S.E., Tan G.D. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care. 2016;39:1777\u20131786. doi: 10.2337/dc16-0650.", "ArticleIdList": ["10.2337/dc16-0650", "27573936"]}, {"Citation": "Iffland K., Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017;2:139\u2013154. doi: 10.1089/can.2016.0034.", "ArticleIdList": ["10.1089/can.2016.0034", "PMC5569602", "28861514"]}, {"Citation": "Vecchinni Rodr\u00edguez C.M., Escalona Y., Flores-Otero J. Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues. Adv. Exp. Med. Biol. 2021;1297:43\u201364. doi: 10.1007/978-3-030-61663-2_4.", "ArticleIdList": ["10.1007/978-3-030-61663-2_4", "PMC8502072", "33537936"]}, {"Citation": "Volkow N.D., Baler R.D., Compton W.M., Weiss S.R.B. Adverse Health Effects of Marijuana Use. N. Engl. J. Med. 2014;370:2219\u20132227. doi: 10.1056/NEJMra1402309.", "ArticleIdList": ["10.1056/NEJMra1402309", "PMC4827335", "24897085"]}, {"Citation": "Wong G., Greenhalgh T., Westhorp G., Pawson R. Development of Methodological Guidance, Publication Standards and Training Materials for Realist and Meta-Narrative Reviews: The RAMESES (Realist and Meta-Narrative Evidence Syntheses\u2014Evolving Standards) Project. NIHR Journals Library; Southampton, UK: 2014. Health Services and Delivery Research.", "ArticleIdList": ["25642521"]}, {"Citation": "Lee Y.H. Strengths and Limitations of Meta-Analysis. Korean J. Med. 2019;94:391\u2013395. doi: 10.3904/kjm.2019.94.5.391.", "ArticleIdList": ["10.3904/kjm.2019.94.5.391"]}, {"Citation": "Baethge C., Goldbeck-Wood S., Mertens S. SANRA\u2014A Scale for the Quality Assessment of Narrative Review Articles. Res. Integr. Peer Rev. 2019;4:5. doi: 10.1186/s41073-019-0064-8.", "ArticleIdList": ["10.1186/s41073-019-0064-8", "PMC6434870", "30962953"]}, {"Citation": "Sirven J.I. Epilepsy: A Spectrum Disorder. Cold Spring Harb. Perspect. Med. 2015;5:a022848. doi: 10.1101/cshperspect.a022848.", "ArticleIdList": ["10.1101/cshperspect.a022848", "PMC4561391", "26328931"]}, {"Citation": "Beghi E. The Epidemiology of Epilepsy. Neuroepidemiology. 2020;54:185\u2013191. doi: 10.1159/000503831.", "ArticleIdList": ["10.1159/000503831", "31852003"]}, {"Citation": "Heron S.E., Scheffer I.E., Berkovic S.F., Dibbens L.M., Mulley J.C. Channelopathies in Idiopathic Epilepsy. Neurotherapeutics. 2007;4:295\u2013304. doi: 10.1016/j.nurt.2007.01.009.", "ArticleIdList": ["10.1016/j.nurt.2007.01.009", "17395140"]}, {"Citation": "Cavirani B., Spagnoli C., Caraffi S.G., Cavalli A., Cesaroni C.A., Cutillo G., De Giorgis V., Frattini D., Marchetti G.B., Masnada S., et al. Genetic Epilepsies and Developmental Epileptic Encephalopathies with Early Onset: A Multicenter Study. Int. J. Mol. Sci. 2024;25:1248. doi: 10.3390/ijms25021248.", "ArticleIdList": ["10.3390/ijms25021248", "PMC10816990", "38279250"]}, {"Citation": "Chen T.-S., Huang T.-H., Lai M.-C., Huang C.-W. The Role of Glutamate Receptors in Epilepsy. Biomedicines. 2023;11:783. doi: 10.3390/biomedicines11030783.", "ArticleIdList": ["10.3390/biomedicines11030783", "PMC10045847", "36979762"]}, {"Citation": "Mele M., Costa R.O., Duarte C.B. Alterations in GABAA-Receptor Trafficking and Synaptic Dysfunction in Brain Disorders. Front. Cell. Neurosci. 2019;13:77. doi: 10.3389/fncel.2019.00077.", "ArticleIdList": ["10.3389/fncel.2019.00077", "PMC6416223", "30899215"]}, {"Citation": "Hanada T. Ionotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors. Biomolecules. 2020;10:464. doi: 10.3390/biom10030464.", "ArticleIdList": ["10.3390/biom10030464", "PMC7175173", "32197322"]}, {"Citation": "Akyuz E., Polat A.K., Eroglu E., Kullu I., Angelopoulou E., Paudel Y.N. Revisiting the Role of Neurotransmitters in Epilepsy: An Updated Review. Life Sci. 2021;265:118826. doi: 10.1016/j.lfs.2020.118826.", "ArticleIdList": ["10.1016/j.lfs.2020.118826", "33259863"]}, {"Citation": "Sumadewi K.T., Harkitasari S., Tjandra D.C. Biomolecular Mechanisms of Epileptic Seizures and Epilepsy: A Review. Acta Epileptol. 2023;5:28. doi: 10.1186/s42494-023-00137-0.", "ArticleIdList": ["10.1186/s42494-023-00137-0"]}, {"Citation": "Foiadelli T., Santangelo A., Costagliola G., Costa E., Scacciati M., Riva A., Volpedo G., Smaldone M., Bonuccelli A., Clemente A.M., et al. Neuroinflammation and Status Epilepticus: A Narrative Review Unraveling a Complex Interplay. Front. Pediatr. 2023;11:1251914. doi: 10.3389/fped.2023.1251914.", "ArticleIdList": ["10.3389/fped.2023.1251914", "PMC10703175", "38078329"]}, {"Citation": "Borowicz-Reutt K.K., Czuczwar S.J. Role of Oxidative Stress in Epileptogenesis and Potential Implications for Therapy. Pharmacol. Rep. 2020;72:1218\u20131226. doi: 10.1007/s43440-020-00143-w.", "ArticleIdList": ["10.1007/s43440-020-00143-w", "PMC7550371", "32865811"]}, {"Citation": "Henshall D.C., Kobow K. Epigenetics and Epilepsy. Cold Spring Harb. Perspect. Med. 2015;5:a022731. doi: 10.1101/cshperspect.a022731.", "ArticleIdList": ["10.1101/cshperspect.a022731", "PMC4665035", "26438606"]}, {"Citation": "Tzadok M., Uliel-Siboni S., Linder I., Kramer U., Epstein O., Menascu S., Nissenkorn A., Yosef O.B., Hyman E., Granot D., et al. CBD-Enriched Medical Cannabis for Intractable Pediatric Epilepsy: The Current Israeli Experience. Seizure. 2016;35:41\u201344. doi: 10.1016/j.seizure.2016.01.004.", "ArticleIdList": ["10.1016/j.seizure.2016.01.004", "26800377"]}, {"Citation": "Porcari G.S., Fu C., Doll E.D., Carter E.G., Carson R.P. Efficacy of Artisanal Preparations of Cannabidiol for the Treatment of Epilepsy: Practical Experiences in a Tertiary Medical Center. Epilepsy Behav. 2018;80:240\u2013246. doi: 10.1016/j.yebeh.2018.01.026.", "ArticleIdList": ["10.1016/j.yebeh.2018.01.026", "29429908"]}, {"Citation": "Pamplona F.A., da Silva L.R., Coan A.C. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-Analysis. Front. Neurol. 2018;9:759. doi: 10.3389/fneur.2018.00759.", "ArticleIdList": ["10.3389/fneur.2018.00759", "PMC6143706", "30258398"]}, {"Citation": "Dravet C., Oguni H. Dravet Syndrome (Severe Myoclonic Epilepsy in Infancy) Handb. Clin. Neurol. 2013;111:627\u2013633. doi: 10.1016/B978-0-444-52891-9.00065-8.", "ArticleIdList": ["10.1016/B978-0-444-52891-9.00065-8", "23622210"]}, {"Citation": "Xu C., Zhang Y., Gozal D., Carney P. Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol. J. Cent. Nerv. Syst. Dis. 2021;13:11795735211048045. doi: 10.1177/11795735211048045.", "ArticleIdList": ["10.1177/11795735211048045", "PMC8724990", "34992485"]}, {"Citation": "Devinsky O., Cross J.H., Laux L., Marsh E., Miller I., Nabbout R., Scheffer I.E., Thiele E.A., Wright S., Cannabidiol in Dravet Syndrome Study Group Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N. Engl. J. Med. 2017;376:2011\u20132020. doi: 10.1056/NEJMoa1611618.", "ArticleIdList": ["10.1056/NEJMoa1611618", "28538134"]}, {"Citation": "Gray R.A., Whalley B.J. The Proposed Mechanisms of Action of CBD in Epilepsy. Epileptic Disord. 2020;22:S10\u2013S15. doi: 10.1684/epd.2020.1135.", "ArticleIdList": ["10.1684/epd.2020.1135", "32053110"]}, {"Citation": "Sharir H., Abood M.E. Pharmacological Characterization of GPR55, a Putative Cannabinoid Receptor. Pharmacol. Ther. 2010;126:301\u2013313. doi: 10.1016/j.pharmthera.2010.02.004.", "ArticleIdList": ["10.1016/j.pharmthera.2010.02.004", "PMC2874616", "20298715"]}, {"Citation": "Rosenberg E.C., Chamberland S., Bazelot M., Nebet E.R., Wang X., McKenzie S., Jain S., Greenhill S., Wilson M., Marley N., et al. Cannabidiol Modulates Excitatory-Inhibitory Ratio to Counter Hippocampal Hyperactivity. Neuron. 2023;111:1282\u20131300.e8. doi: 10.1016/j.neuron.2023.01.018.", "ArticleIdList": ["10.1016/j.neuron.2023.01.018", "36787750"]}, {"Citation": "Xing J., Li J. TRPV1 Receptor Mediates Glutamatergic Synaptic Input to Dorsolateral Periaqueductal Gray (Dl-PAG) Neurons. J. Neurophysiol. 2007;97:503\u2013511. doi: 10.1152/jn.01023.2006.", "ArticleIdList": ["10.1152/jn.01023.2006", "17065246"]}, {"Citation": "De Petrocellis L., Ligresti A., Moriello A.S., Allar\u00e0 M., Bisogno T., Petrosino S., Stott C.G., Di Marzo V. Effects of Cannabinoids and Cannabinoid-Enriched Cannabis Extracts on TRP Channels and Endocannabinoid Metabolic Enzymes. Br. J. Pharmacol. 2011;163:1479\u20131494. doi: 10.1111/j.1476-5381.2010.01166.x.", "ArticleIdList": ["10.1111/j.1476-5381.2010.01166.x", "PMC3165957", "21175579"]}, {"Citation": "Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., Di Marzo V. Molecular Targets for Cannabidiol and Its Synthetic Analogues: Effect on Vanilloid VR1 Receptors and on the Cellular Uptake and Enzymatic Hydrolysis of Anandamide. Br. J. Pharmacol. 2001;134:845\u2013852. doi: 10.1038/sj.bjp.0704327.", "ArticleIdList": ["10.1038/sj.bjp.0704327", "PMC1573017", "11606325"]}, {"Citation": "Mori F., Ribolsi M., Kusayanagi H., Monteleone F., Mantovani V., Buttari F., Marasco E., Bernardi G., Maccarrone M., Centonze D. TRPV1 Channels Regulate Cortical Excitability in Humans. J. Neurosci. 2012;32:873\u2013879. doi: 10.1523/JNEUROSCI.2531-11.2012.", "ArticleIdList": ["10.1523/JNEUROSCI.2531-11.2012", "PMC6621142", "22262885"]}, {"Citation": "Sun F.-J., Guo W., Zheng D.-H., Zhang C.-Q., Li S., Liu S.-Y., Yin Q., Yang H., Shu H.-F. Increased Expression of TRPV1 in the Cortex and Hippocampus from Patients with Mesial Temporal Lobe Epilepsy. J. Mol. Neurosci. 2013;49:182\u2013193. doi: 10.1007/s12031-012-9878-2.", "ArticleIdList": ["10.1007/s12031-012-9878-2", "22936245"]}, {"Citation": "Iannotti F.A., Hill C.L., Leo A., Alhusaini A., Soubrane C., Mazzarella E., Russo E., Whalley B.J., Di Marzo V., Stephens G.J. Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability. ACS Chem. Neurosci. 2014;5:1131\u20131141. doi: 10.1021/cn5000524.", "ArticleIdList": ["10.1021/cn5000524", "25029033"]}, {"Citation": "The Effect of a Pharmaceutical Formulation of Pure Cannabidiol on Human CNS Expressed Voltage Gated Sodium Channels.  [(accessed on 9 April 2024)].  Available online:  https://aesnet.org/abstractslisting/the-effect-of-a-pharmaceutical-formulation-of-pure-cannabidiol-on-human-cns-expressed-voltage-gated-sodium-channels."}, {"Citation": "Dunwiddie T.V. Endogenously Released Adenosine Regulates Excitability in the in Vitro Hippocampus. Epilepsia. 1980;21:541\u2013548. doi: 10.1111/j.1528-1157.1980.tb04305.x.", "ArticleIdList": ["10.1111/j.1528-1157.1980.tb04305.x", "7418669"]}, {"Citation": "Fredholm B.B., Chen J.-F., Cunha R.A., Svenningsson P., Vaugeois J.-M. Adenosine and Brain Function. Int. Rev. Neurobiol. 2005;63:191\u2013270. doi: 10.1016/S0074-7742(05)63007-3.", "ArticleIdList": ["10.1016/S0074-7742(05)63007-3", "15797469"]}, {"Citation": "Sebasti\u00e3o A.M., Ribeiro J.A. Adenosine Receptors in Health and Disease. Springer; Berlin/Heidelberg, Germany: 2009. Adenosine Receptors and the Central Nervous System; pp. 471\u2013534.", "ArticleIdList": ["10.1007/978-3-540-89615-9_16", "19639292"]}, {"Citation": "Lotankar S., Prabhavalkar K.S., Bhatt L.K. Biomarkers for Parkinson\u2019s Disease: Recent Advancement. Neurosci. Bull. 2017;33:585\u2013597. doi: 10.1007/s12264-017-0183-5.", "ArticleIdList": ["10.1007/s12264-017-0183-5", "PMC5636742", "28936761"]}, {"Citation": "Radhakrishnan D.M., Goyal V. Parkinson\u2019s Disease: A Review. Neurol. India. 2018;66:S26\u2013S35. doi: 10.4103/0028-3886.226451.", "ArticleIdList": ["10.4103/0028-3886.226451", "29503325"]}, {"Citation": "Marras C., Beck J.C., Bower J.H., Roberts E., Ritz B., Ross G.W., Abbott R.D., Savica R., Van Den Eeden S.K., Willis A.W., et al. Prevalence of Parkinson\u2019s Disease across North America. NPJ Park. Dis. 2018;4:21. doi: 10.1038/s41531-018-0058-0.", "ArticleIdList": ["10.1038/s41531-018-0058-0", "PMC6039505", "30003140"]}, {"Citation": "Surmeier D.J. Determinants of Dopaminergic Neuron Loss in Parkinson\u2019s Disease. FEBS J. 2018;285:3657\u20133668. doi: 10.1111/febs.14607.", "ArticleIdList": ["10.1111/febs.14607", "PMC6546423", "30028088"]}, {"Citation": "Calabresi P., Mechelli A., Natale G., Volpicelli-Daley L., Di Lazzaro G., Ghiglieri V. Alpha-Synuclein in Parkinson\u2019s Disease and Other Synucleinopathies: From Overt Neurodegeneration Back to Early Synaptic Dysfunction. Cell Death Dis. 2023;14:176. doi: 10.1038/s41419-023-05672-9.", "ArticleIdList": ["10.1038/s41419-023-05672-9", "PMC9977911", "36859484"]}, {"Citation": "Chen C., Turnbull D.M., Reeve A.K. Mitochondrial Dysfunction in Parkinson\u2019s Disease\u2014Cause or Consequence? Biology. 2019;8:38. doi: 10.3390/biology8020038.", "ArticleIdList": ["10.3390/biology8020038", "PMC6627981", "31083583"]}, {"Citation": "Chen X., Guo C., Kong J. Oxidative Stress in Neurodegenerative Diseases. Neural Regen. Res. 2012;7:376\u2013385. doi: 10.3969/j.issn.1673-5374.2012.05.009.", "ArticleIdList": ["10.3969/j.issn.1673-5374.2012.05.009", "PMC4350122", "25774178"]}, {"Citation": "Isik S., Yeman Kiyak B., Akbayir R., Seyhali R., Arpaci T. Microglia Mediated Neuroinflammation in Parkinson\u2019s Disease. Cells. 2023;12:1012. doi: 10.3390/cells12071012.", "ArticleIdList": ["10.3390/cells12071012", "PMC10093562", "37048085"]}, {"Citation": "Ebrahimi-Fakhari D., Cantuti-Castelvetri I., Fan Z., Rockenstein E., Masliah E., Hyman B.T., McLean P.J., Unni V.K. Distinct Roles In Vivo for the Ubiquitin\u2013Proteasome System and the Autophagy\u2013Lysosomal Pathway in the Degradation of \u03b1-Synuclein. J. Neurosci. 2011;31:14508\u201314520. doi: 10.1523/JNEUROSCI.1560-11.2011.", "ArticleIdList": ["10.1523/JNEUROSCI.1560-11.2011", "PMC3587176", "21994367"]}, {"Citation": "Ihara Y., Morishima-Kawashima M., Nixon R. The Ubiquitin\u2013Proteasome System and the Autophagic\u2013Lysosomal System in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2012;2:a006361. doi: 10.1101/cshperspect.a006361.", "ArticleIdList": ["10.1101/cshperspect.a006361", "PMC3405832", "22908190"]}, {"Citation": "Teixeira D., Cardoso I.L., Teixeira D., Cardoso I.L. Genes Involved in the Development of Parkinson. Open J. Park. Dis. Treat. 2017;1:39\u201351. doi: 10.17352/ojpdt.000005.", "ArticleIdList": ["10.17352/ojpdt.000005"]}, {"Citation": "Ball N., Teo W.-P., Chandra S., Chapman J. Parkinson\u2019s Disease and the Environment. Front. Neurol. 2019;10:218. doi: 10.3389/fneur.2019.00218.", "ArticleIdList": ["10.3389/fneur.2019.00218", "PMC6433887", "30941085"]}, {"Citation": "Sousa A., DiFrancisco-Donoghue J. Cannabidiol and Tetrahydrocannabinol Use in Parkinson\u2019s Disease: An Observational Pilot Study. Cureus. 2023;15:e42391. doi: 10.7759/cureus.42391.", "ArticleIdList": ["10.7759/cureus.42391", "PMC10446505", "37621812"]}, {"Citation": "Venderov\u00e1 K., R\u016fzicka E., Vor\u00edsek V., Visnovsk\u00fd P. Survey on Cannabis Use in Parkinson\u2019s Disease: Subjective Improvement of Motor Symptoms. Mov. Disord. 2004;19:1102\u20131106. doi: 10.1002/mds.20111.", "ArticleIdList": ["10.1002/mds.20111", "15372606"]}, {"Citation": "More S.V., Choi D.-K. Promising Cannabinoid-Based Therapies for Parkinson\u2019s Disease: Motor Symptoms to Neuroprotection. Mol. Neurodegener. 2015;10:17. doi: 10.1186/s13024-015-0012-0.", "ArticleIdList": ["10.1186/s13024-015-0012-0", "PMC4404240", "25888232"]}, {"Citation": "Stampanoni Bassi M., Sancesario A., Morace R., Centonze D., Iezzi E. Cannabinoids in Parkinson\u2019s Disease. Cannabis Cannabinoid Res. 2017;2:21\u201329. doi: 10.1089/can.2017.0002.", "ArticleIdList": ["10.1089/can.2017.0002", "PMC5436333", "28861502"]}, {"Citation": "Lotan I., Treves T.A., Roditi Y., Djaldetti R. Cannabis (Medical Marijuana) Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: An Open-Label Observational Study. Clin. Neuropharmacol. 2014;37:41\u201344. doi: 10.1097/WNF.0000000000000016.", "ArticleIdList": ["10.1097/WNF.0000000000000016", "24614667"]}, {"Citation": "Segovia G., Mora F., Crossman A.R., Brotchie J.M. Effects of CB1 Cannabinoid Receptor Modulating Compounds on the Hyperkinesia Induced by High-Dose Levodopa in the Reserpine-Treated Rat Model of Parkinson\u2019s Disease. Mov. Disord. 2003;18:138\u2013149. doi: 10.1002/mds.10312.", "ArticleIdList": ["10.1002/mds.10312", "12539206"]}, {"Citation": "van Vliet S.A.M., Vanwersch R.A.P., Jongsma M.J., Olivier B., Philippens I.H.C.H.M. Therapeutic Effects of Delta9-THC and Modafinil in a Marmoset Parkinson Model. Eur. Neuropsychopharmacol. 2008;18:383\u2013389. doi: 10.1016/j.euroneuro.2007.11.003.", "ArticleIdList": ["10.1016/j.euroneuro.2007.11.003", "18222654"]}, {"Citation": "Kreitzer A.C., Malenka R.C. Endocannabinoid-Mediated Rescue of Striatal LTD and Motor Deficits in Parkinson\u2019s Disease Models. Nature. 2007;445:643\u2013647. doi: 10.1038/nature05506.", "ArticleIdList": ["10.1038/nature05506", "17287809"]}, {"Citation": "Brotchie J.M. Adjuncts to Dopamine Replacement: A Pragmatic Approach to Reducing the Problem of Dyskinesia in Parkinson\u2019s Disease. Mov. Disord. 1998;13:871\u2013876. doi: 10.1002/mds.870130603.", "ArticleIdList": ["10.1002/mds.870130603", "9827609"]}, {"Citation": "Fernandez-Espejo E., Caraballo I., Rodriguez de Fonseca F., Ferrer B., Banoua F.E., Flores J.A., Galan-Rodriguez B. Experimental Parkinsonism Alters Anandamide Precursor Synthesis, and Functional Deficits Are Improved by AM404: A Modulator of Endocannabinoid Function. Neuropsychopharmacol. 2004;29:1134\u20131142. doi: 10.1038/sj.npp.1300407.", "ArticleIdList": ["10.1038/sj.npp.1300407", "15010694"]}, {"Citation": "Garc\u00eda-Arencibia M., Ferraro L., Tanganelli S., Fern\u00e1ndez-Ruiz J. Enhanced Striatal Glutamate Release after the Administration of Rimonabant to 6-Hydroxydopamine-Lesioned Rats. Neurosci. Lett. 2008;438:10\u201313. doi: 10.1016/j.neulet.2008.04.041.", "ArticleIdList": ["10.1016/j.neulet.2008.04.041", "18457923"]}, {"Citation": "van der Stelt M., Fox S.H., Hill M., Crossman A.R., Petrosino S., Di Marzo V., Brotchie J.M. A Role for Endocannabinoids in the Generation of Parkinsonism and Levodopa-Induced Dyskinesia in MPTP-Lesioned Non-Human Primate Models of Parkinson\u2019s Disease. FASEB J. 2005;19:1140\u20131142. doi: 10.1096/fj.04-3010fje.", "ArticleIdList": ["10.1096/fj.04-3010fje", "15894565"]}, {"Citation": "Fernandez-Espejo E., Caraballo I., de Fonseca F.R., El Banoua F., Ferrer B., Flores J.A., Galan-Rodriguez B. Cannabinoid CB1 Antagonists Possess Antiparkinsonian Efficacy Only in Rats with Very Severe Nigral Lesion in Experimental Parkinsonism. Neurobiol. Dis. 2005;18:591\u2013601. doi: 10.1016/j.nbd.2004.10.015.", "ArticleIdList": ["10.1016/j.nbd.2004.10.015", "15755685"]}, {"Citation": "Gonz\u00e1lez S., Scorticati C., Garc\u00eda-Arencibia M., de Miguel R., Ramos J.A., Fern\u00e1ndez-Ruiz J. Effects of Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, in a Rat Model of Parkinson\u2019s Disease. Brain Res. 2006;1073\u20131074:209\u2013219. doi: 10.1016/j.brainres.2005.12.014.", "ArticleIdList": ["10.1016/j.brainres.2005.12.014", "16412990"]}, {"Citation": "Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., Brotchie J.M. Enhanced Levels of Endogenous Cannabinoids in the Globus Pallidus Are Associated with a Reduction in Movement in an Animal Model of Parkinson\u2019s Disease. FASEB J. 2000;14:1432\u20131438. doi: 10.1096/fj.14.10.1432.", "ArticleIdList": ["10.1096/fj.14.10.1432", "10877836"]}, {"Citation": "Lastres-Becker I., Cebeira M., de Ceballos M.L., Zeng B.Y., Jenner P., Ramos J.A., Fern\u00e1ndez-Ruiz J.J. Increased Cannabinoid CB1 Receptor Binding and Activation of GTP-Binding Proteins in the Basal Ganglia of Patients with Parkinson\u2019s Syndrome and of MPTP-Treated Marmosets. Eur. J. Neurosci. 2001;14:1827\u20131832. doi: 10.1046/j.0953-816x.2001.01812.x.", "ArticleIdList": ["10.1046/j.0953-816x.2001.01812.x", "11860478"]}, {"Citation": "Sierra S., Luquin N., Rico A.J., G\u00f3mez-Bautista V., Roda E., Dopeso-Reyes I.G., V\u00e1zquez A., Mart\u00ednez-Pinilla E., Labandeira-Garc\u00eda J.L., Franco R., et al. Detection of Cannabinoid Receptors CB1 and CB2 within Basal Ganglia Output Neurons in Macaques: Changes Following Experimental Parkinsonism. Brain Struct. Funct. 2015;220:2721\u20132738. doi: 10.1007/s00429-014-0823-8.", "ArticleIdList": ["10.1007/s00429-014-0823-8", "PMC4549378", "24972960"]}, {"Citation": "Zeng B.Y., Dass B., Owen A., Rose S., Cannizzaro C., Tel B.C., Jenner P. Chronic L-DOPA Treatment Increases Striatal Cannabinoid CB1 Receptor mRNA Expression in 6-Hydroxydopamine-Lesioned Rats. Neurosci. Lett. 1999;276:71\u201374. doi: 10.1016/s0304-3940(99)00762-4.", "ArticleIdList": ["10.1016/s0304-3940(99)00762-4", "10624794"]}, {"Citation": "Fox S.H., Henry B., Hill M., Crossman A., Brotchie J. Stimulation of Cannabinoid Receptors Reduces Levodopa-Induced Dyskinesia in the MPTP-Lesioned Nonhuman Primate Model of Parkinson\u2019s Disease. Mov. Disord. 2002;17:1180\u20131187. doi: 10.1002/mds.10289.", "ArticleIdList": ["10.1002/mds.10289", "12465055"]}, {"Citation": "Ferrer B., Asbrock N., Kathuria S., Piomelli D., Giuffrida A. Effects of Levodopa on Endocannabinoid Levels in Rat Basal Ganglia: Implications for the Treatment of Levodopa-Induced Dyskinesias. Eur. J. Neurosci. 2003;18:1607\u20131614. doi: 10.1046/j.1460-9568.2003.02896.x.", "ArticleIdList": ["10.1046/j.1460-9568.2003.02896.x", "14511339"]}, {"Citation": "Morgese M.G., Cassano T., Cuomo V., Giuffrida A. Anti-Dyskinetic Effects of Cannabinoids in a Rat Model of Parkinson\u2019s Disease: Role of CB1 and TRPV1 Receptors. Exp. Neurol. 2007;208:110\u2013119. doi: 10.1016/j.expneurol.2007.07.021.", "ArticleIdList": ["10.1016/j.expneurol.2007.07.021", "PMC2128772", "17900568"]}, {"Citation": "Alex M., Teresa M., Grazia M.M., Trabace L., Andrea G. The Cannabinoid Agonist WIN55212-2 Decreases L-DOPA-Induced PKA Activation and Dyskinetic Behavior in 6-OHDA-Treated Rats. Neurosci. Res. 2012;72:236\u2013242. doi: 10.1016/j.neures.2011.12.006.", "ArticleIdList": ["10.1016/j.neures.2011.12.006", "PMC3273613", "22192465"]}, {"Citation": "Walsh S., Gorman A.M., Finn D.P., Dowd E. The Effects of Cannabinoid Drugs on Abnormal Involuntary Movements in Dyskinetic and Non-Dyskinetic 6-Hydroxydopamine Lesioned Rats. Brain Res. 2010;1363:40\u201348. doi: 10.1016/j.brainres.2010.09.086.", "ArticleIdList": ["10.1016/j.brainres.2010.09.086", "20888328"]}, {"Citation": "Martinez A.A., Morgese M.G., Pisanu A., Macheda T., Paquette M.A., Seillier A., Cassano T., Carta A.R., Giuffrida A. Activation of PPAR Gamma Receptors Reduces Levodopa-Induced Dyskinesias in 6-OHDA-Lesioned Rats. Neurobiol. Dis. 2015;74:295\u2013304. doi: 10.1016/j.nbd.2014.11.024.", "ArticleIdList": ["10.1016/j.nbd.2014.11.024", "PMC4323744", "25486547"]}, {"Citation": "Gonz\u00e1lez-Aparicio R., Moratalla R. Oleoylethanolamide Reduces L-DOPA-Induced Dyskinesia via TRPV1 Receptor in a Mouse Model of Parkinson\u2019s Disease. Neurobiol. Dis. 2014;62:416\u2013425. doi: 10.1016/j.nbd.2013.10.008.", "ArticleIdList": ["10.1016/j.nbd.2013.10.008", "24140894"]}, {"Citation": "Zhang X.-X., Tian Y., Wang Z.-T., Ma Y.-H., Tan L., Yu J.-T. The Epidemiology of Alzheimer\u2019s Disease Modifiable Risk Factors and Prevention. J. Prev. Alzheimers Dis. 2021;8:313\u2013321. doi: 10.14283/jpad.2021.15.", "ArticleIdList": ["10.14283/jpad.2021.15", "34101789"]}, {"Citation": "Kumar A., Sidhu J., Goyal A., Tsao J.W. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2024. Alzheimer Disease."}, {"Citation": "Andrade-Guerrero J., Santiago-Balmaseda A., Jeronimo-Aguilar P., Vargas-Rodr\u00edguez I., Cadena-Su\u00e1rez A.R., S\u00e1nchez-Garibay C., Pozo-Molina G., M\u00e9ndez-Catal\u00e1 C.F., Cardenas-Aguayo M.-C., Diaz-Cintra S., et al. Alzheimer\u2019s Disease: An Updated Overview of Its Genetics. Int. J. Mol. Sci. 2023;24:3754. doi: 10.3390/ijms24043754.", "ArticleIdList": ["10.3390/ijms24043754", "PMC9966419", "36835161"]}, {"Citation": "Herrmann N., Ruthirakuhan M., Gallagher D., Verhoeff N.P.L.G., Kiss A., Black S.E., Lanct\u00f4t K.L. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer\u2019s Disease. Am. J. Geriatr. Psychiatry. 2019;27:1161\u20131173. doi: 10.1016/j.jagp.2019.05.002.", "ArticleIdList": ["10.1016/j.jagp.2019.05.002", "31182351"]}, {"Citation": "van den Elsen G.A., Tobben L., Ahmed A.I., Verkes R.J., Kramers C., Marijnissen R.M., Olde Rikkert M.G., van der Marck M.A. Effects of Tetrahydrocannabinol on Balance and Gait in Patients with Dementia: A Randomised Controlled Crossover Trial. J. Psychopharmacol. 2017;31:184\u2013191. doi: 10.1177/0269881116665357.", "ArticleIdList": ["10.1177/0269881116665357", "27624148"]}, {"Citation": "Kendall D.A., Yudowski G.A. Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Front. Cell. Neurosci. 2017;10:294. doi: 10.3389/fncel.2016.00294.", "ArticleIdList": ["10.3389/fncel.2016.00294", "PMC5209363", "28101004"]}, {"Citation": "Esposito G., De Filippis D., Maiuri M.C., De Stefano D., Carnuccio R., Iuvone T. Cannabidiol Inhibits Inducible Nitric Oxide Synthase Protein Expression and Nitric Oxide Production in Beta-Amyloid Stimulated PC12 Neurons through P38 MAP Kinase and NF-kappaB Involvement. Neurosci. Lett. 2006;399:91\u201395. doi: 10.1016/j.neulet.2006.01.047.", "ArticleIdList": ["10.1016/j.neulet.2006.01.047", "16490313"]}, {"Citation": "Libro R., Diomede F., Scionti D., Piattelli A., Grassi G., Pollastro F., Bramanti P., Mazzon E., Trubiani O. Cannabidiol Modulates the Expression of Alzheimer\u2019s Disease-Related Genes in Mesenchymal Stem Cells. Int. J. Mol. Sci. 2016;18:26. doi: 10.3390/ijms18010026.", "ArticleIdList": ["10.3390/ijms18010026", "PMC5297661", "28025562"]}, {"Citation": "Scuderi C., Steardo L., Esposito G. Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells through PPAR\u03b3 Involvement. Phytother. Res. 2014;28:1007\u20131013. doi: 10.1002/ptr.5095.", "ArticleIdList": ["10.1002/ptr.5095", "24288245"]}, {"Citation": "da Silva V.K., de Freitas B.S., da Silva Dornelles A., Nery L.R., Falavigna L., Ferreira R.D.P., Bogo M.R., Hallak J.E.C., Zuardi A.W., Crippa J.A.S., et al. Cannabidiol Normalizes Caspase 3, Synaptophysin, and Mitochondrial Fission Protein DNM1L Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection. Mol. Neurobiol. 2014;49:222\u2013233. doi: 10.1007/s12035-013-8514-7.", "ArticleIdList": ["10.1007/s12035-013-8514-7", "23893294"]}, {"Citation": "da Silva V.K., de Freitas B.S., Garcia R.C.L., Monteiro R.T., Hallak J.E., Zuardi A.W., Crippa J.A.S., Schr\u00f6der N. Antiapoptotic Effects of Cannabidiol in an Experimental Model of Cognitive Decline Induced by Brain Iron Overload. Transl. Psychiatry. 2018;8:176. doi: 10.1038/s41398-018-0232-5.", "ArticleIdList": ["10.1038/s41398-018-0232-5", "PMC6120904", "30177808"]}, {"Citation": "Schubert D., Kepchia D., Liang Z., Dargusch R., Goldberg J., Maher P. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer\u2019s Disease. Mol. Neurobiol. 2019;56:7719\u20137730. doi: 10.1007/s12035-019-1637-8.", "ArticleIdList": ["10.1007/s12035-019-1637-8", "PMC6815693", "31104297"]}, {"Citation": "Liang Z., Soriano-Castell D., Kepchia D., Duggan B.M., Currais A., Schubert D., Maher P. Cannabinol Inhibits Oxytosis/Ferroptosis by Directly Targeting Mitochondria Independently of Cannabinoid Receptors. Free Radic. Biol. Med. 2022;180:33\u201351. doi: 10.1016/j.freeradbiomed.2022.01.001.", "ArticleIdList": ["10.1016/j.freeradbiomed.2022.01.001", "PMC8840979", "34999187"]}, {"Citation": "Tafti D., Ehsan M., Xixis K.L. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2024. Multiple Sclerosis.", "ArticleIdList": ["29763024"]}, {"Citation": "Waubant E., Lucas R., Mowry E., Graves J., Olsson T., Alfredsson L., Langer-Gould A. Environmental and Genetic Risk Factors for MS: An Integrated Review. Ann. Clin. Transl. Neurol. 2019;6:1905\u20131922. doi: 10.1002/acn3.50862.", "ArticleIdList": ["10.1002/acn3.50862", "PMC6764632", "31392849"]}, {"Citation": "Patsopoulos N.A., Barcellos L.F., Hintzen R.Q., Schaefer C., van Duijn C.M., Noble J.A., Raj T., IMSGC. ANZgene. Gourraud P.-A., et al. Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects. PLoS Genet. 2013;9:e1003926. doi: 10.1371/journal.pgen.1003926.", "ArticleIdList": ["10.1371/journal.pgen.1003926", "PMC3836799", "24278027"]}, {"Citation": "Gomez-Gaitan E.A., Garcia-Ortega Y.E., Salda\u00f1a-Cruz A.M., Contreras-Haro B., Gamez-Nava J.I., Perez-Guerrero E.E., Nava-Valdivia C.A., Gallardo-Moya S., Martinez-Hernandez A., Gonzalez Lopez L., et al. Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study. Int. J. Mol. Sci. 2023;24:14594. doi: 10.3390/ijms241914594.", "ArticleIdList": ["10.3390/ijms241914594", "PMC10572793", "37834042"]}, {"Citation": "Costantino C.M., Hutton J., Baecher-Allan C., Hafler D.A. Multiple Sclerosis and Regulatory T Cells. J. Clin. Immunol. 2008;28:697\u2013706. doi: 10.1007/s10875-008-9236-x.", "ArticleIdList": ["10.1007/s10875-008-9236-x", "PMC2752287", "18763026"]}, {"Citation": "Trapp B.D., Nave K.-A. Multiple Sclerosis: An Immune or Neurodegenerative Disorder? Annu. Rev. Neurosci. 2008;31:247\u2013269. doi: 10.1146/annurev.neuro.30.051606.094313.", "ArticleIdList": ["10.1146/annurev.neuro.30.051606.094313", "18558855"]}, {"Citation": "Haddad F., Dokmak G., Karaman R. The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms. Life. 2022;12:682. doi: 10.3390/life12050682.", "ArticleIdList": ["10.3390/life12050682", "PMC9148011", "35629350"]}, {"Citation": "Kraft G.H., Freal J.E., Coryell J.K. Disability, Disease Duration, and Rehabilitation Service Needs in Multiple Sclerosis: Patient Perspectives. Arch. Phys. Med. Rehabil. 1986;67:164\u2013168. doi: 10.1016/0003-9993(86)90060-2.", "ArticleIdList": ["10.1016/0003-9993(86)90060-2", "3954578"]}, {"Citation": "Filippini G., Minozzi S., Borrelli F., Cinquini M., Dwan K. Cannabis and Cannabinoids for Symptomatic Treatment for People with Multiple Sclerosis. Cochrane Database Syst. Rev. 2022;5:CD013444. doi: 10.1002/14651858.CD013444.pub2.", "ArticleIdList": ["10.1002/14651858.CD013444.pub2", "PMC9069991", "35510826"]}, {"Citation": "Rainka M.M., Aladeen T.S., Mattle A.G., Lewandowski E., Vanini D., McCormack K., Mechtler L. Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population. Int. J. MS Care. 2023;25:111\u2013117. doi: 10.7224/1537-2073.2022-006.", "ArticleIdList": ["10.7224/1537-2073.2022-006", "PMC10211357", "37250194"]}, {"Citation": "Zajicek J.P., Hobart J.C., Slade A., Barnes D., Mattison P.G., MUSEC Research Group Multiple Sclerosis and Extract of Cannabis: Results of the MUSEC Trial. J. Neurol. Neurosurg. Psychiatry. 2012;83:1125\u20131132. doi: 10.1136/jnnp-2012-302468.", "ArticleIdList": ["10.1136/jnnp-2012-302468", "22791906"]}, {"Citation": "Afshar B., Khalifehzadeh-Esfahani Z., Seyfizadeh N., Rezaei Danbaran G., Hemmatzadeh M., Mohammadi H. The Role of Immune Regulatory Molecules in Multiple Sclerosis. J. Neuroimmunol. 2019;337:577061. doi: 10.1016/j.jneuroim.2019.577061.", "ArticleIdList": ["10.1016/j.jneuroim.2019.577061", "31520791"]}, {"Citation": "Luo C., Jian C., Liao Y., Huang Q., Wu Y., Liu X., Zou D., Wu Y. The Role of Microglia in Multiple Sclerosis. Neuropsychiatr. Dis. Treat. 2017;13:1661\u20131667. doi: 10.2147/NDT.S140634.", "ArticleIdList": ["10.2147/NDT.S140634", "PMC5499932", "28721047"]}, {"Citation": "Turcotte C., Blanchet M.-R., Laviolette M., Flamand N. The CB2 Receptor and Its Role as a Regulator of Inflammation. Cell. Mol. Life Sci. 2016;73:4449\u20134470. doi: 10.1007/s00018-016-2300-4.", "ArticleIdList": ["10.1007/s00018-016-2300-4", "PMC5075023", "27402121"]}, {"Citation": "Klein T.W., Newton C., Zhu W., Daaka Y., Friedman H. Delta 9-Tetrahydrocannabinol, Cytokines, and Immunity to Legionella Pneumophila. Proc. Soc. Exp. Biol. Med. 1995;209:205\u2013212. doi: 10.3181/00379727-209-43897b.", "ArticleIdList": ["10.3181/00379727-209-43897b", "7777582"]}, {"Citation": "Derocq J.M., S\u00e9gui M., Marchand J., Le Fur G., Casellas P. Cannabinoids Enhance Human B-Cell Growth at Low Nanomolar Concentrations. FEBS Lett. 1995;369:177\u2013182. doi: 10.1016/0014-5793(95)00746-v.", "ArticleIdList": ["10.1016/0014-5793(95)00746-v", "7544292"]}, {"Citation": "Nagarkatti P., Pandey R., Rieder S.A., Hegde V.L., Nagarkatti M. Cannabinoids as Novel Anti-Inflammatory Drugs. Future Med. Chem. 2009;1:1333\u20131349. doi: 10.4155/fmc.09.93.", "ArticleIdList": ["10.4155/fmc.09.93", "PMC2828614", "20191092"]}, {"Citation": "Ramirez S.H., Hask\u00f3 J., Skuba A., Fan S., Dykstra H., McCormick R., Reichenbach N., Krizbai I., Mahadevan A., Zhang M., et al. Activation of Cannabinoid Receptor 2 Attenuates Leukocyte-Endothelial Cell Interactions and Blood-Brain Barrier Dysfunction under Inflammatory Conditions. J. Neurosci. 2012;32:4004\u20134016. doi: 10.1523/JNEUROSCI.4628-11.2012.", "ArticleIdList": ["10.1523/JNEUROSCI.4628-11.2012", "PMC3325902", "22442067"]}, {"Citation": "Pacher P., Mechoulam R. Is Lipid Signaling through Cannabinoid 2 Receptors Part of a Protective System? Prog. Lipid Res. 2011;50:193\u2013211. doi: 10.1016/j.plipres.2011.01.001.", "ArticleIdList": ["10.1016/j.plipres.2011.01.001", "PMC3062638", "21295074"]}, {"Citation": "Dulamea A.O. Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis. Adv. Exp. Med. Biol. 2017;958:91\u2013127. doi: 10.1007/978-3-319-47861-6_7.", "ArticleIdList": ["10.1007/978-3-319-47861-6_7", "28093710"]}, {"Citation": "Lombardi M., Scaroni F., Gabrielli M., Raffaele S., Bonfanti E., Filipello F., Giussani P., Picciolini S., de Rosbo N.K., Uccelli A., et al. Extracellular Vesicles Released by Microglia and Macrophages Carry Endocannabinoids Which Foster Oligodendrocyte Differentiation. Front. Immunol. 2024;15:1331210. doi: 10.3389/fimmu.2024.1331210.", "ArticleIdList": ["10.3389/fimmu.2024.1331210", "PMC10921360", "38464529"]}, {"Citation": "van der Stelt M., Veldhuis W.B., B\u00e4r P.R., Veldink G.A., Vliegenthart J.F.G., Nicolay K. Neuroprotection by \u03949-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity. J. Neurosci. 2001;21:6475\u20136479. doi: 10.1523/JNEUROSCI.21-17-06475.2001.", "ArticleIdList": ["10.1523/JNEUROSCI.21-17-06475.2001", "PMC6763099", "11517236"]}, {"Citation": "Kubiliene A., Mickute K., Baranauskaite J., Marksa M., Liekis A., Sadauskiene I. The Effects of Cannabis Sativa L. Extract on Oxidative Stress Markers In Vivo. Life. 2021;11:647. doi: 10.3390/life11070647.", "ArticleIdList": ["10.3390/life11070647", "PMC8303441", "34357019"]}, {"Citation": "Lacroix C., Guilhaumou R., Micallef J., Bruneteau G., Desnuelle C., Blin O. Cannabis for the Treatment of Amyotrophic Lateral Sclerosis: What Is the Patients\u2019 View? Rev. Neurol. 2023;179:967\u2013974. doi: 10.1016/j.neurol.2023.03.018.", "ArticleIdList": ["10.1016/j.neurol.2023.03.018", "37460332"]}, {"Citation": "\u0160t\u011btk\u00e1\u0159ov\u00e1 I., Ehler E. Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date. Diagnostics. 2021;11:231. doi: 10.3390/diagnostics11020231.", "ArticleIdList": ["10.3390/diagnostics11020231", "PMC7913557", "33546386"]}, {"Citation": "Doi Y., Atsuta N., Sobue G., Morita M., Nakano I. Prevalence and Incidence of Amyotrophic Lateral Sclerosis in Japan. J. Epidemiol. 2014;24:494\u2013499. doi: 10.2188/jea.JE20140059.", "ArticleIdList": ["10.2188/jea.JE20140059", "PMC4213224", "25373461"]}, {"Citation": "Riva N., Mora G., Sorar\u00f9 G., Lunetta C., Ferraro O.E., Falzone Y., Leocani L., Fazio R., Comola M., Comi G., et al. Safety and Efficacy of Nabiximols on Spasticity Symptoms in Patients with Motor Neuron Disease (CANALS): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. Lancet Neurol. 2019;18:155\u2013164. doi: 10.1016/S1474-4422(18)30406-X.", "ArticleIdList": ["10.1016/S1474-4422(18)30406-X", "30554828"]}, {"Citation": "McIntosh C.S., Li D., Wilton S.D., Aung-Htut M.T. Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies. Biomedicines. 2021;9:1499. doi: 10.3390/biomedicines9111499.", "ArticleIdList": ["10.3390/biomedicines9111499", "PMC8615177", "34829728"]}, {"Citation": "Jiang A., Handley R.R., Lehnert K., Snell R.G. From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington\u2019s Disease Research. Int. J. Mol. Sci. 2023;24:13021. doi: 10.3390/ijms241613021.", "ArticleIdList": ["10.3390/ijms241613021", "PMC10455900", "37629202"]}, {"Citation": "Mart\u00ed-Mart\u00ednez S., Valor L.M. A Glimpse of Molecular Biomarkers in Huntington\u2019s Disease. Int. J. Mol. Sci. 2022;23:5411. doi: 10.3390/ijms23105411.", "ArticleIdList": ["10.3390/ijms23105411", "PMC9142992", "35628221"]}, {"Citation": "Fiszer A., Nowak B. Strategie wyciszania ekspresji zmutowanego genu w terapii choroby Huntingtona: Inhibicja genu huntingtyny. Post\u0119py Biochem. 2020;66:1\u20139. doi: 10.18388/pb.2020_313.", "ArticleIdList": ["10.18388/pb.2020_313", "33320475"]}, {"Citation": "Medina A., Mahjoub Y., Shaver L., Pringsheim T. Prevalence and Incidence of Huntington\u2019s Disease: An Updated Systematic Review and Meta-Analysis. Mov. Disord. 2022;37:2327\u20132335. doi: 10.1002/mds.29228.", "ArticleIdList": ["10.1002/mds.29228", "PMC10086981", "36161673"]}, {"Citation": "Polyglutamine (PolyQ) Diseases: Genetics to Treatments.  [(accessed on 25 January 2024)].  Available online:  https://journals.sagepub.com/doi/epub/10.3727/096368914x678454.", "ArticleIdList": ["10.3727/096368914x678454"]}, {"Citation": "Aguareles J., Para\u00edso-Luna J., Palomares B., Bajo-Gra\u00f1eras R., Navarrete C., Ruiz-Calvo A., Garc\u00eda-Rinc\u00f3n D., Garc\u00eda-Taboada E., Guzm\u00e1n M., Mu\u00f1oz E., et al. Oral Administration of the Cannabigerol Derivative VCE-003.2 Promotes Subventricular Zone Neurogenesis and Protects against Mutant Huntingtin-Induced Neurodegeneration. Transl. Neurodegener. 2019;8:9. doi: 10.1186/s40035-019-0148-x.", "ArticleIdList": ["10.1186/s40035-019-0148-x", "PMC6407204", "30899454"]}, {"Citation": "Valdeolivas S., Navarrete C., Cantarero I., Bellido M.L., Mu\u00f1oz E., Sagredo O. Neuroprotective Properties of Cannabigerol in Huntington\u2019s Disease: Studies in R6/2 Mice and 3-Nitropropionate-Lesioned Mice. Neurotherapeutics. 2015;12:185\u2013199. doi: 10.1007/s13311-014-0304-z.", "ArticleIdList": ["10.1007/s13311-014-0304-z", "PMC4322067", "25252936"]}, {"Citation": "Stone N.L., Murphy A.J., England T.J., O\u2019Sullivan S.E. A Systematic Review of Minor Phytocannabinoids with Promising Neuroprotective Potential. Br. J. Pharmacol. 2020;177:4330\u20134352. doi: 10.1111/bph.15185.", "ArticleIdList": ["10.1111/bph.15185", "PMC7484504", "32608035"]}, {"Citation": "Parrella N.-F., Hill A.T., Enticott P.G., Barhoun P., Bower I.S., Ford T.C. A Systematic Review of Cannabidiol Trials in Neurodevelopmental Disorders. Pharmacol. Biochem. Behav. 2023;230:173607. doi: 10.1016/j.pbb.2023.173607.", "ArticleIdList": ["10.1016/j.pbb.2023.173607", "37543051"]}, {"Citation": "M\u00e1rquez-Caraveo M.E., Rodr\u00edguez-Valent\u00edn R., P\u00e9rez-Barr\u00f3n V., V\u00e1zquez-Salas R.A., S\u00e1nchez-Ferrer J.C., De Castro F., Allen-Leigh B., Lazcano-Ponce E. Children and Adolescents with Neurodevelopmental Disorders Show Cognitive Heterogeneity and Require a Person-Centered Approach. Sci. Rep. 2021;11:18463. doi: 10.1038/s41598-021-97551-6.", "ArticleIdList": ["10.1038/s41598-021-97551-6", "PMC8445997", "34531454"]}, {"Citation": "Barchel D., Stolar O., De-Haan T., Ziv-Baran T., Saban N., Fuchs D.O., Koren G., Berkovitch M. Oral Cannabidiol Use in Children with Autism Spectrum Disorder to Treat Related Symptoms and Co-Morbidities. Front. Pharmacol. 2018;9:1521. doi: 10.3389/fphar.2018.01521.", "ArticleIdList": ["10.3389/fphar.2018.01521", "PMC6333745", "30687090"]}, {"Citation": "Aran A., Cayam-Rand D. Medical Cannabis in Children. Rambam. Maimonides Med. J. 2020;11:e0003. doi: 10.5041/RMMJ.10386.", "ArticleIdList": ["10.5041/RMMJ.10386", "PMC7000154", "32017680"]}, {"Citation": "de Freitas F.D., Pimenta S., Soares S., Gonzaga D., Vaz-Matos I., Prior C. El Papel de Los Cannabinoides En Los Trastornos Del Neurodesarrollo de Ni\u00f1os y Adolescentes. Rev. Neurol. 2022;75:189\u2013197. doi: 10.33588/rn.7507.2022123.", "ArticleIdList": ["10.33588/rn.7507.2022123", "PMC10280758", "36169325"]}, {"Citation": "Magnus W., Nazir S., Anilkumar A.C., Shaban K. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2024. Attention Deficit Hyperactivity Disorder.", "ArticleIdList": ["28722868"]}, {"Citation": "Turiaco F., Cullotta C., Mannino F., Bruno A., Squadrito F., Pallio G., Irrera N. Attention Deficit Hyperactivity Disorder (ADHD) and Polyphenols: A Systematic Review. Int. J. Mol. Sci. 2024;25:1536. doi: 10.3390/ijms25031536.", "ArticleIdList": ["10.3390/ijms25031536", "PMC10855440", "38338814"]}, {"Citation": "Cooper R.E., Williams E., Seegobin S., Tye C., Kuntsi J., Asherson P. Cannabinoids in Attention-Deficit/Hyperactivity Disorder: A Randomised-Controlled Trial. Eur. Neuropsychopharmacol. 2017;27:795\u2013808. doi: 10.1016/j.euroneuro.2017.05.005.", "ArticleIdList": ["10.1016/j.euroneuro.2017.05.005", "28576350"]}, {"Citation": "Rasmussen J., Casey B.J., van Erp T.G.M., Tamm L., Epstein J.N., Buss C., Bjork J.M., Molina B.S.G., Velanova K., Mathalon D.H., et al. ADHD and Cannabis Use in Young Adults Examined Using fMRI of a Go/NoGo Task. Brain Imaging Behav. 2016;10:761\u2013771. doi: 10.1007/s11682-015-9438-9.", "ArticleIdList": ["10.1007/s11682-015-9438-9", "PMC4840078", "26489976"]}, {"Citation": "Bossong M.G., Mehta M.A., van Berckel B.N.M., Howes O.D., Kahn R.S., Stokes P.R.A. Further Human Evidence for Striatal Dopamine Release Induced by Administration of \u22069-Tetrahydrocannabinol (THC): Selectivity to Limbic Striatum. Psychopharmacology. 2015;232:2723\u20132729. doi: 10.1007/s00213-015-3915-0.", "ArticleIdList": ["10.1007/s00213-015-3915-0", "PMC4816196", "25801289"]}, {"Citation": "Bossong M.G., van Berckel B.N.M., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., van Gerven J.M.A., Ramsey N.F., Lammertsma A.A., Kahn R.S. Delta 9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Neuropsychopharmacology. 2009;34:759\u2013766. doi: 10.1038/npp.2008.138.", "ArticleIdList": ["10.1038/npp.2008.138", "18754005"]}, {"Citation": "Voruganti L.N., Slomka P., Zabel P., Mattar A., Awad A.G. Cannabis Induced Dopamine Release: An in-Vivo SPECT Study. Psychiatry Res. 2001;107:173\u2013177. doi: 10.1016/s0925-4927(01)00104-4.", "ArticleIdList": ["10.1016/s0925-4927(01)00104-4", "11566433"]}, {"Citation": "Volkow N.D., Wang G.-J., Tomasi D., Kollins S.H., Wigal T.L., Newcorn J.H., Telang F.W., Fowler J.S., Logan J., Wong C.T., et al. Methylphenidate-Elicited Dopamine Increases in Ventral Striatum Are Associated with Long-Term Symptom Improvement in Adults with Attention Deficit Hyperactivity Disorder. J. Neurosci. 2012;32:841\u2013849. doi: 10.1523/JNEUROSCI.4461-11.2012.", "ArticleIdList": ["10.1523/JNEUROSCI.4461-11.2012", "PMC3350870", "22262882"]}, {"Citation": "Stokes P.R.A., Egerton A., Watson B., Reid A., Breen G., Lingford-Hughes A., Nutt D.J., Mehta M.A. Significant Decreases in Frontal and Temporal [11C]-Raclopride Binding after THC Challenge. Neuroimage. 2010;52:1521\u20131527. doi: 10.1016/j.neuroimage.2010.04.274.", "ArticleIdList": ["10.1016/j.neuroimage.2010.04.274", "20451621"]}, {"Citation": "Barkus E., Morrison P.D., Vuletic D., Dickson J.C., Ell P.J., Pilowsky L.S., Brenneisen R., Holt D.W., Powell J., Kapur S., et al. Does Intravenous \u03949-Tetrahydrocannabinol Increase Dopamine Release? A SPET Study. J. Psychopharmacol. 2011;25:1462\u20131468. doi: 10.1177/0269881110382465.", "ArticleIdList": ["10.1177/0269881110382465", "20851843"]}, {"Citation": "Strohbeck-K\u00fchner P., Skopp G., Mattern R. Cannabis Improves Symptoms of ADHD. Cannabinoids. 2008;3:1\u20133."}, {"Citation": "Hupli A.M.M. Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Med. Cannabis Cannabinoids. 2019;1:112\u2013118. doi: 10.1159/000495307.", "ArticleIdList": ["10.1159/000495307", "PMC8489316", "34676327"]}, {"Citation": "Motlani V., Motlani G., Thool A. Asperger Syndrome (AS): A Review Article. Cureus. 2022;14:e31395. doi: 10.7759/cureus.31395.", "ArticleIdList": ["10.7759/cureus.31395", "PMC9742637", "36514569"]}, {"Citation": "Mirkovic B., G\u00e9rardin P. Asperger\u2019s Syndrome: What to Consider? Encephale. 2019;45:169\u2013174. doi: 10.1016/j.encep.2018.11.005.", "ArticleIdList": ["10.1016/j.encep.2018.11.005", "30736970"]}, {"Citation": "Aran A., Cassuto H., Lubotzky A., Wattad N., Hazan E. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study. J. Autism. Dev. Disord. 2019;49:1284\u20131288. doi: 10.1007/s10803-018-3808-2.", "ArticleIdList": ["10.1007/s10803-018-3808-2", "30382443"]}, {"Citation": "Fleury-Teixeira P., Caixeta F.V., Ramires da Silva L.C., Brasil-Neto J.P., Malcher-Lopes R. Effects of CBD-Enriched Cannabis Sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use. Front. Neurol. 2019;10:1145. doi: 10.3389/fneur.2019.01145.", "ArticleIdList": ["10.3389/fneur.2019.01145", "PMC6834767", "31736860"]}, {"Citation": "Bar-Lev Schleider L., Mechoulam R., Saban N., Meiri G., Novack V. Real Life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Sci. Rep. 2019;9:200. doi: 10.1038/s41598-018-37570-y.", "ArticleIdList": ["10.1038/s41598-018-37570-y", "PMC6336869", "30655581"]}, {"Citation": "Kwan Cheung K.A., Mitchell M.D., Heussler H.S. Cannabidiol and Neurodevelopmental Disorders in Children. Front. Psychiatry. 2021;12:643442. doi: 10.3389/fpsyt.2021.643442.", "ArticleIdList": ["10.3389/fpsyt.2021.643442", "PMC8175856", "34093265"]}, {"Citation": "Panayotis N., Ehinger Y., Felix M.S., Roux J.-C. State-of-the-Art Therapies for Rett Syndrome. Dev. Med. Child. Neurol. 2023;65:162\u2013170. doi: 10.1111/dmcn.15383.", "ArticleIdList": ["10.1111/dmcn.15383", "PMC10087176", "36056801"]}, {"Citation": "Chahil G., Bollu P.C. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2024. Rett Syndrome.", "ArticleIdList": ["29489169"]}, {"Citation": "Desnous B., Beretti T., Muller N., Neveu J., Villeneuve N., L\u00e9pine A., Daquin G., Milh M. Efficacy and Tolerance of Cannabidiol in the Treatment of Epilepsy in Patients with Rett Syndrome. Epilepsia Open. 2024;9:397\u2013403. doi: 10.1002/epi4.12796.", "ArticleIdList": ["10.1002/epi4.12796", "PMC10839357", "37485779"]}, {"Citation": "Kerr D.M., Downey L., Conboy M., Finn D.P., Roche M. Alterations in the Endocannabinoid System in the Rat Valproic Acid Model of Autism. Behav. Brain Res. 2013;249:124\u2013132. doi: 10.1016/j.bbr.2013.04.043.", "ArticleIdList": ["10.1016/j.bbr.2013.04.043", "23643692"]}, {"Citation": "Karhson D.S., Krasinska K.M., Dallaire J.A., Libove R.A., Phillips J.M., Chien A.S., Garner J.P., Hardan A.Y., Parker K.J. Plasma Anandamide Concentrations Are Lower in Children with Autism Spectrum Disorder. Mol. Autism. 2018;9:18. doi: 10.1186/s13229-018-0203-y.", "ArticleIdList": ["10.1186/s13229-018-0203-y", "PMC5848550", "29564080"]}, {"Citation": "Servadio M., Melancia F., Manduca A., di Masi A., Schiavi S., Cartocci V., Pallottini V., Campolongo P., Ascenzi P., Trezza V. Targeting Anandamide Metabolism Rescues Core and Associated Autistic-like Symptoms in Rats Prenatally Exposed to Valproic Acid. Transl. Psychiatry. 2016;6:e902. doi: 10.1038/tp.2016.182.", "ArticleIdList": ["10.1038/tp.2016.182", "PMC5048215", "27676443"]}, {"Citation": "Marco E.M., Macr\u00ec S., Laviola G. Critical Age Windows for Neurodevelopmental Psychiatric Disorders: Evidence from Animal Models. Neurotox. Res. 2011;19:286\u2013307. doi: 10.1007/s12640-010-9205-z.", "ArticleIdList": ["10.1007/s12640-010-9205-z", "20607469"]}, {"Citation": "Frye R.E., Casanova M.F., Fatemi S.H., Folsom T.D., Reutiman T.J., Brown G.L., Edelson S.M., Slattery J.C., Adams J.B. Neuropathological Mechanisms of Seizures in Autism Spectrum Disorder. Front. Neurosci. 2016;10:192. doi: 10.3389/fnins.2016.00192.", "ArticleIdList": ["10.3389/fnins.2016.00192", "PMC4861974", "27242398"]}, {"Citation": "Cifelli P., Ruffolo G., De Felice E., Alfano V., van Vliet E.A., Aronica E., Palma E. Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission? Int. J. Mol. Sci. 2020;21:723. doi: 10.3390/ijms21030723.", "ArticleIdList": ["10.3390/ijms21030723", "PMC7038116", "31979108"]}, {"Citation": "Silvestro S., Mammana S., Cavalli E., Bramanti P., Mazzon E. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules. 2019;24:1459. doi: 10.3390/molecules24081459.", "ArticleIdList": ["10.3390/molecules24081459", "PMC6514832", "31013866"]}, {"Citation": "Lai M.-C., Kassee C., Besney R., Bonato S., Hull L., Mandy W., Szatmari P., Ameis S.H. Prevalence of Co-Occurring Mental Health Diagnoses in the Autism Population: A Systematic Review and Meta-Analysis. Lancet Psychiatry. 2019;6:819\u2013829. doi: 10.1016/S2215-0366(19)30289-5.", "ArticleIdList": ["10.1016/S2215-0366(19)30289-5", "31447415"]}, {"Citation": "Linge R., Jim\u00e9nez-S\u00e1nchez L., Campa L., Pilar-Cu\u00e9llar F., Vidal R., Pazos A., Adell A., D\u00edaz \u00c1. Cannabidiol Induces Rapid-Acting Antidepressant-like Effects and Enhances Cortical 5-HT/Glutamate Neurotransmission: Role of 5-HT1A Receptors. Neuropharmacology. 2016;103:16\u201326. doi: 10.1016/j.neuropharm.2015.12.017.", "ArticleIdList": ["10.1016/j.neuropharm.2015.12.017", "26711860"]}, {"Citation": "Russo E.B., Burnett A., Hall B., Parker K.K. Agonistic Properties of Cannabidiol at 5-HT1a Receptors. Neurochem. Res. 2005;30:1037\u20131043. doi: 10.1007/s11064-005-6978-1.", "ArticleIdList": ["10.1007/s11064-005-6978-1", "16258853"]}, {"Citation": "Oluwabusi O.O., Parke S., Ambrosini P.J. Tourette Syndrome Associated with Attention Deficit Hyperactivity Disorder: The Impact of Tics and Psychopharmacological Treatment Options. World J. Clin. Pediatr. 2016;5:128\u2013135. doi: 10.5409/wjcp.v5.i1.128.", "ArticleIdList": ["10.5409/wjcp.v5.i1.128", "PMC4737687", "26862512"]}, {"Citation": "Set K.K., Warner J.N. Tourette Syndrome in Children: An Update. Curr. Probl. Pediatr. Adolesc. Health Care. 2021;51:101032. doi: 10.1016/j.cppeds.2021.101032.", "ArticleIdList": ["10.1016/j.cppeds.2021.101032", "34305006"]}, {"Citation": "M\u00fcller-Vahl K.R., Schneider U., Koblenz A., J\u00f6bges M., Kolbe H., Daldrup T., Emrich H.M. Treatment of Tourette\u2019s Syndrome with Delta 9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial. Pharmacopsychiatry. 2002;35:57\u201361. doi: 10.1055/s-2002-25028.", "ArticleIdList": ["10.1055/s-2002-25028", "11951146"]}, {"Citation": "Anis S., Zalomek C., Korczyn A.D., Rosenberg A., Giladi N., Gurevich T. Medical Cannabis for Gilles de La Tourette Syndrome: An Open-Label Prospective Study. Behav. Neurol. 2022;2022:5141773. doi: 10.1155/2022/5141773.", "ArticleIdList": ["10.1155/2022/5141773", "PMC8926524", "35310886"]}, {"Citation": "Abi-Jaoude E., Bhikram T., Parveen F., Levenbach J., Lafreniere-Roula M., Sandor P. A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. Cannabis Cannabinoid Res. 2023;8:835\u2013845. doi: 10.1089/can.2022.0091.", "ArticleIdList": ["10.1089/can.2022.0091", "36040329"]}, {"Citation": "L\u00f3pez-Ram\u00edrez G., S\u00e1nchez-Zavaleta R., \u00c1valos-Fuentes A., Jos\u00e9 Sierra J., Paz-Berm\u00fadez F., Leyva-G\u00f3mez G., Segovia Vila J., Cort\u00e9s H., Flor\u00e1n B. D2 Autoreceptor Switches CB2 Receptor Effects on [3H]-Dopamine Release in the Striatum. Synapse. 2020;74:e22139. doi: 10.1002/syn.22139.", "ArticleIdList": ["10.1002/syn.22139", "31610050"]}, {"Citation": "Gong J.-P., Onaivi E., Ishiguro H., Liu Q.-R., Tagliaferro P., Brusco A., Uhl G. Cannabinoid CB2 Receptors: Immunohistochemical Localization in Rat Brain. Brain Res. 2006;1071:10\u201323. doi: 10.1016/j.brainres.2005.11.035.", "ArticleIdList": ["10.1016/j.brainres.2005.11.035", "16472786"]}, {"Citation": "Lanciego J., Barroso-Chinea P., Rico A.J., Conte L., Call\u00e9n L., Roda E., G\u00f3mez-Bautista V., Lopez I., Lluis C., Labandeira-Garcia J., et al. Expression of the mRNA Coding the Cannabinoid Receptor 2 in the Pallidal Complex of Macaca Fascicularis. J. Psychopharmacol. 2011;25:97\u2013104. doi: 10.1177/0269881110367732.", "ArticleIdList": ["10.1177/0269881110367732", "20488834"]}, {"Citation": "Bova A., Gaidica M., Hurst A., Iwai Y., Hunter J., Leventhal D.K. Precisely Timed Dopamine Signals Establish Distinct Kinematic Representations of Skilled Movements. eLife. 2020;9:e61591. doi: 10.7554/eLife.61591.", "ArticleIdList": ["10.7554/eLife.61591", "PMC7861618", "33245045"]}, {"Citation": "Alvarez B.D., Cavazos C., Morales C.A., Lopez S.M., Amodeo D.A. Impact of Specific Serotonin Receptor Modulation on Restricted Repetitive Behaviors. Front. Behav. Neurosci. 2022;16:1078983. doi: 10.3389/fnbeh.2022.1078983.", "ArticleIdList": ["10.3389/fnbeh.2022.1078983", "PMC9816668", "36620862"]}, {"Citation": "Gorberg V., Borisov V., Greig I.R., Pertwee R.G., McCaffery P., Anavi-Goffer S. Motor-like Tics Are Mediated by CB2 Cannabinoid Receptor-Dependent and Independent Mechanisms Associated with Age and Sex. Mol. Neurobiol. 2022;59:5070\u20135083. doi: 10.1007/s12035-022-02884-6.", "ArticleIdList": ["10.1007/s12035-022-02884-6", "PMC9363400", "35666403"]}, {"Citation": "M\u00fcller-Vahl K.R., Bindila L., Lutz B., Musshoff F., Skripuletz T., Baumgaertel C., S\u00fchs K.-W. Cerebrospinal Fluid Endocannabinoid Levels in Gilles de La Tourette Syndrome. Neuropsychopharmacology. 2020;45:1323\u20131329. doi: 10.1038/s41386-020-0671-6.", "ArticleIdList": ["10.1038/s41386-020-0671-6", "PMC7297729", "32272483"]}, {"Citation": "Depression and Other Common Mental Disorders: Global Health Estimates. 2017.  [(accessed on 27 February 2024)].  Available online:  https://www.afro.who.int/publications/depression-and-other-common-mental-disorders-global-health-estimates-2017."}, {"Citation": "Haller J. Anxiety Modulation by Cannabinoids\u2014The Role of Stress Responses and Coping. Int. J. Mol. Sci. 2023;24:15777. doi: 10.3390/ijms242115777.", "ArticleIdList": ["10.3390/ijms242115777", "PMC10650718", "37958761"]}, {"Citation": "Hill M.N., McEwen B.S. Involvement of the Endocannabinoid System in the Neurobehavioural Effects of Stress and Glucocorticoids. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010;34:791\u2013797. doi: 10.1016/j.pnpbp.2009.11.001.", "ArticleIdList": ["10.1016/j.pnpbp.2009.11.001", "PMC2945244", "19903506"]}, {"Citation": "Lutz B., Marsicano G., Maldonado R., Hillard C.J. The Endocannabinoid System in Guarding against Fear, Anxiety and Stress. Nat. Rev. Neurosci. 2015;16:705\u2013718. doi: 10.1038/nrn4036.", "ArticleIdList": ["10.1038/nrn4036", "PMC5871913", "26585799"]}, {"Citation": "Aliczki M., Haller J. Interactions between Cannabinoid Signaling and Anxiety: A Comparative Analysis of Intervention Tools and Behavioral Effects. Springer; Berlin/Heidelberg, Germany: 2015. pp. 73\u201396.", "ArticleIdList": ["10.1007/978-1-4939-2294-9_4"]}, {"Citation": "Barsky A.J. Defining Psychiatry in Primary Care: Origins, Opportunities, and Obstacles. Compr. Psychiatry. 1980;21:221\u2013232. doi: 10.1016/0010-440X(80)90006-1.", "ArticleIdList": ["10.1016/0010-440X(80)90006-1", "7379514"]}, {"Citation": "Shannon S., Lewis N., Lee H., Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm. J. 2019;23:18\u2013041. doi: 10.7812/TPP/18-041.", "ArticleIdList": ["10.7812/TPP/18-041", "PMC6326553", "30624194"]}, {"Citation": "Hundal H., Lister R., Evans N., Antley A., Englund A., Murray R.M., Freeman D., Morrison P.D. The Effects of Cannabidiol on Persecutory Ideation and Anxiety in a High Trait Paranoid Group. J. Psychopharmacol. 2018;32:276\u2013282. doi: 10.1177/0269881117737400.", "ArticleIdList": ["10.1177/0269881117737400", "29086614"]}, {"Citation": "Ibeas Bih C., Chen T., Nunn A.V.W., Bazelot M., Dallas M., Whalley B.J. Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015;12:699\u2013730. doi: 10.1007/s13311-015-0377-3.", "ArticleIdList": ["10.1007/s13311-015-0377-3", "PMC4604182", "26264914"]}, {"Citation": "Blessing E.M., Steenkamp M.M., Manzanares J., Marmar C.R. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12:825\u2013836. doi: 10.1007/s13311-015-0387-1.", "ArticleIdList": ["10.1007/s13311-015-0387-1", "PMC4604171", "26341731"]}, {"Citation": "Papagianni E.P., Stevenson C.W. Cannabinoid Regulation of Fear and Anxiety: An Update. Curr. Psychiatry Rep. 2019;21:38. doi: 10.1007/s11920-019-1026-z.", "ArticleIdList": ["10.1007/s11920-019-1026-z", "PMC6486906", "31030284"]}, {"Citation": "Lee J.L.C., Bertoglio L.J., Guimar\u00e3es F.S., Stevenson C.W. Cannabidiol Regulation of Emotion and Emotional Memory Processing: Relevance for Treating Anxiety-related and Substance Abuse Disorders. Br. J. Pharmacol. 2017;174:3242\u20133256. doi: 10.1111/bph.13724.", "ArticleIdList": ["10.1111/bph.13724", "PMC5595771", "28268256"]}, {"Citation": "Campos A.C., Guimar\u00e3es F.S. Involvement of 5HT1A Receptors in the Anxiolytic-like Effects of Cannabidiol Injected into the Dorsolateral Periaqueductal Gray of Rats. Psychopharmacology. 2008;199:223\u2013230. doi: 10.1007/s00213-008-1168-x.", "ArticleIdList": ["10.1007/s00213-008-1168-x", "18446323"]}, {"Citation": "Rantala M.J., Luoto S., Krams I., Karlsson H. Depression Subtyping Based on Evolutionary Psychiatry: Proximate Mechanisms and Ultimate Functions. Brain Behav. Immun. 2018;69:603\u2013617. doi: 10.1016/j.bbi.2017.10.012.", "ArticleIdList": ["10.1016/j.bbi.2017.10.012", "29051086"]}, {"Citation": "Bilbao A., Spanagel R. Medical Cannabinoids: A Pharmacology-Based Systematic Review and Meta-Analysis for All Relevant Medical Indications. BMC Med. 2022;20:259. doi: 10.1186/s12916-022-02459-1.", "ArticleIdList": ["10.1186/s12916-022-02459-1", "PMC9389720", "35982439"]}, {"Citation": "Allsop D.J., Copeland J., Lintzeris N., Dunlop A.J., Montebello M., Sadler C., Rivas G.R., Holland R.M., Muhleisen P., Norberg M.M., et al. Nabiximols as an Agonist Replacement Therapy during Cannabis Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry. 2014;71:281\u2013291. doi: 10.1001/jamapsychiatry.2013.3947.", "ArticleIdList": ["10.1001/jamapsychiatry.2013.3947", "24430917"]}, {"Citation": "Trigo J.M., Soliman A., Quilty L.C., Fischer B., Rehm J., Selby P., Barnes A.J., Huestis M.A., George T.P., Streiner D.L., et al. Nabiximols Combined with Motivational Enhancement/Cognitive Behavioral Therapy for the Treatment of Cannabis Dependence: A Pilot Randomized Clinical Trial. PLoS ONE. 2018;13:e0190768. doi: 10.1371/journal.pone.0190768.", "ArticleIdList": ["10.1371/journal.pone.0190768", "PMC5791962", "29385147"]}, {"Citation": "Lev-Ran S., Roerecke M., Le Foll B., George T.P., McKenzie K., Rehm J. The Association between Cannabis Use and Depression: A Systematic Review and Meta-Analysis of Longitudinal Studies. Psychol. Med. 2014;44:797\u2013810. doi: 10.1017/S0033291713001438.", "ArticleIdList": ["10.1017/S0033291713001438", "23795762"]}, {"Citation": "Sarris J., Sinclair J., Karamacoska D., Davidson M., Firth J. Medicinal Cannabis for Psychiatric Disorders: A Clinically-Focused Systematic Review. BMC Psychiatry. 2020;20:24. doi: 10.1186/s12888-019-2409-8.", "ArticleIdList": ["10.1186/s12888-019-2409-8", "PMC6966847", "31948424"]}, {"Citation": "Bryant R.A. Post-traumatic Stress Disorder: A State-of-the-art Review of Evidence and Challenges. World Psychiatry. 2019;18:259\u2013269. doi: 10.1002/wps.20656.", "ArticleIdList": ["10.1002/wps.20656", "PMC6732680", "31496089"]}, {"Citation": "Yehuda R., Hoge C.W., McFarlane A.C., Vermetten E., Lanius R.A., Nievergelt C.M., Hobfoll S.E., Koenen K.C., Neylan T.C., Hyman S.E. Post-Traumatic Stress Disorder. Nat. Rev. Dis. Primers. 2015;1:15057. doi: 10.1038/nrdp.2015.57.", "ArticleIdList": ["10.1038/nrdp.2015.57", "27189040"]}, {"Citation": "Jetly R., Heber A., Fraser G., Boisvert D. The Efficacy of Nabilone, a Synthetic Cannabinoid, in the Treatment of PTSD-Associated Nightmares: A Preliminary Randomized, Double-Blind, Placebo-Controlled Cross-over Design Study. Psychoneuroendocrinology. 2015;51:585\u2013588. doi: 10.1016/j.psyneuen.2014.11.002.", "ArticleIdList": ["10.1016/j.psyneuen.2014.11.002", "25467221"]}, {"Citation": "Bonn-Miller M.O., Sisley S., Riggs P., Yazar-Klosinski B., Wang J.B., Loflin M.J.E., Shechet B., Hennigan C., Matthews R., Emerson A., et al. The Short-Term Impact of 3 Smoked Cannabis Preparations versus Placebo on PTSD Symptoms: A Randomized Cross-over Clinical Trial. PLoS ONE. 2021;16:e0246990. doi: 10.1371/journal.pone.0246990.", "ArticleIdList": ["10.1371/journal.pone.0246990", "PMC7968689", "33730032"]}, {"Citation": "Kesner A.J., Mateo Y., Abrahao K.P., Ramos-Maciel S., Pava M.J., Gracias A.L., Paulsen R.T., Carlson H.B., Lovinger D.M. Changes in Striatal Dopamine Release, Sleep, and Behavior during Spontaneous \u0394-9-Tetrahydrocannabinol Abstinence in Male and Female Mice. Neuropsychopharmacology. 2022;47:1537\u20131549. doi: 10.1038/s41386-022-01326-0.", "ArticleIdList": ["10.1038/s41386-022-01326-0", "PMC9205922", "35478010"]}, {"Citation": "Gorelick D.A., Goodwin R.S., Schwilke E., Schroeder J.R., Schwope D.M., Kelly D.L., Ortemann-Renon C., Bonnet D., Huestis M.A. Around-the-Clock Oral THC Effects on Sleep in Male Chronic Daily Cannabis Smokers. Am. J. Addict. 2013;22:510\u2013514. doi: 10.1111/j.1521-0391.2013.12003.x.", "ArticleIdList": ["10.1111/j.1521-0391.2013.12003.x", "PMC4537525", "23952899"]}, {"Citation": "Monti J.M., Pandi-Perumal S.R. Clinical Management of Sleep and Sleep Disorders with Cannabis and Cannabinoids: Implications to Practicing Psychiatrists. Clin. Neuropharmacol. 2022;45:27. doi: 10.1097/WNF.0000000000000494.", "ArticleIdList": ["10.1097/WNF.0000000000000494", "35221321"]}, {"Citation": "Kolla B.P., Hayes L., Cox C., Eatwell L., Deyo-Svendsen M., Mansukhani M.P. The Effects of Cannabinoids on Sleep. J. Prim. Care Community Health. 2022;13:21501319221081277. doi: 10.1177/21501319221081277.", "ArticleIdList": ["10.1177/21501319221081277", "PMC9036386", "35459406"]}, {"Citation": "Kuhathasan N., Minuzzi L., MacKillop J., Frey B.N. The Use of Cannabinoids for Insomnia in Daily Life: Naturalistic Study. J. Med. Internet Res. 2021;23:e25730. doi: 10.2196/25730.", "ArticleIdList": ["10.2196/25730", "PMC8581757", "34704957"]}, {"Citation": "Gupta J., Gaurkar S.S. Migraine: An Underestimated Neurological Condition Affecting Billions. Cureus. 2022;14:e28347. doi: 10.7759/cureus.28347.", "ArticleIdList": ["10.7759/cureus.28347", "PMC9506374", "36168353"]}, {"Citation": "Silvestro M., Iannone L.F., Orologio I., Tessitore A., Tedeschi G., Geppetti P., Russo A. Migraine Treatment: Towards New Pharmacological Targets. Int. J. Mol. Sci. 2023;24:12268. doi: 10.3390/ijms241512268.", "ArticleIdList": ["10.3390/ijms241512268", "PMC10418850", "37569648"]}, {"Citation": "Pescador Ruschel M.A., De Jesus O. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2024. Migraine Headache.", "ArticleIdList": ["32809622"]}, {"Citation": "Stith S.S., Diviant J.P., Brockelman F., Keeling K., Hall B., Lucern S., Vigil J.M. Alleviative Effects of Cannabis Flower on Migraine and Headache. J. Integr. Med. 2020;18:416\u2013424. doi: 10.1016/j.joim.2020.07.004.", "ArticleIdList": ["10.1016/j.joim.2020.07.004", "32758396"]}, {"Citation": "Cuttler C., Spradlin A., Cleveland M.J., Craft R.M. Short- and Long-Term Effects of Cannabis on Headache and Migraine. J. Pain. 2020;21:722\u2013730. doi: 10.1016/j.jpain.2019.11.001.", "ArticleIdList": ["10.1016/j.jpain.2019.11.001", "31715263"]}, {"Citation": "Greco R., Francavilla M., Demartini C., Zanaboni A.M., Sodergren M.H., Facchetti S., Pacchetti B., Palmisani M., Franco V., Tassorelli C. Characterization of the Biochemical and Behavioral Effects of Cannabidiol: Implications for Migraine. J. Headache Pain. 2023;24:48. doi: 10.1186/s10194-023-01589-y.", "ArticleIdList": ["10.1186/s10194-023-01589-y", "PMC10155373", "37138206"]}, {"Citation": "Ribeiro A., Ferraz-de-Paula V., Pinheiro M.L., Vitoretti L.B., Mariano-Souza D.P., Quinteiro-Filho W.M., Akamine A.T., Almeida V.I., Quevedo J., Dal-Pizzol F., et al. Cannabidiol, a Non-Psychotropic Plant-Derived Cannabinoid, Decreases Inflammation in a Murine Model of Acute Lung Injury: Role for the Adenosine A2A Receptor. Eur. J. Pharmacol. 2012;678:78\u201385. doi: 10.1016/j.ejphar.2011.12.043.", "ArticleIdList": ["10.1016/j.ejphar.2011.12.043", "22265864"]}, {"Citation": "Costa B., Colleoni M., Conti S., Parolaro D., Franke C., Trovato A.E., Giagnoni G. Oral Anti-Inflammatory Activity of Cannabidiol, a Non-Psychoactive Constituent of Cannabis, in Acute Carrageenan-Induced Inflammation in the Rat Paw. Naunyn Schmiedebergs Arch. Pharmacol. 2004;369:294\u2013299. doi: 10.1007/s00210-004-0871-3.", "ArticleIdList": ["10.1007/s00210-004-0871-3", "14963641"]}, {"Citation": "Sepulveda D.E., Morris D.P., Raup-Konsavage W.M., Sun D., Vrana K.E., Graziane N.M. Evaluating the Antinociceptive Efficacy of Cannabidiol Alone or in Combination with Morphine Using the Formalin Test in Male and Female Mice. Cannabis Cannabinoid Res. 2022;7:648\u2013657. doi: 10.1089/can.2021.0108.", "ArticleIdList": ["10.1089/can.2021.0108", "PMC9587782", "34846928"]}, {"Citation": "Grotenhermen F. Franjo Grotenhermen. Med. Cannabis Cannabinoids. 2018;1:5. doi: 10.1159/000489141.", "ArticleIdList": ["10.1159/000489141", "PMC8489330", "34676313"]}, {"Citation": "Muller C., Morales P., Reggio P.H. Cannabinoid Ligands Targeting TRP Channels. Front. Mol. Neurosci. 2019;11:487. doi: 10.3389/fnmol.2018.00487.", "ArticleIdList": ["10.3389/fnmol.2018.00487", "PMC6340993", "30697147"]}, {"Citation": "Finnerup N.B., Kuner R., Jensen T.S. Neuropathic Pain: From Mechanisms to Treatment. Physiol. Rev. 2021;101:259\u2013301. doi: 10.1152/physrev.00045.2019.", "ArticleIdList": ["10.1152/physrev.00045.2019", "32584191"]}, {"Citation": "Dykukha I., Malessa R., Essner U., \u00dcberall M.A. Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. Pain Med. 2021;22:861\u2013874. doi: 10.1093/pm/pnab050.", "ArticleIdList": ["10.1093/pm/pnab050", "33561282"]}, {"Citation": "Schimrigk S., Marziniak M., Neubauer C., Kugler E.M., Werner G., Abramov-Sommariva D. Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients. Eur. Neurol. 2017;78:320\u2013329. doi: 10.1159/000481089.", "ArticleIdList": ["10.1159/000481089", "PMC5804828", "29073592"]}, {"Citation": "Wilsey B., Marcotte T., Deutsch R., Gouaux B., Sakai S., Donaghe H. Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. J. Pain. 2013;14:136\u2013148. doi: 10.1016/j.jpain.2012.10.009.", "ArticleIdList": ["10.1016/j.jpain.2012.10.009", "PMC3566631", "23237736"]}, {"Citation": "Pertwee R.G. The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: \u03949-Tetrahydrocannabinol, Cannabidiol and \u03949-Tetrahydrocannabivarin. Br. J. Pharmacol. 2008;153:199\u2013215. doi: 10.1038/sj.bjp.0707442.", "ArticleIdList": ["10.1038/sj.bjp.0707442", "PMC2219532", "17828291"]}, {"Citation": "Borgonetti V., Mugnaini C., Corelli F., Galeotti N. The Selective CB2 Agonist COR167 Reduced Symptoms in a Mice Model of Trauma-Induced Peripheral Neuropathy through HDAC-1 Inhibition. Biomedicines. 2023;11:1546. doi: 10.3390/biomedicines11061546.", "ArticleIdList": ["10.3390/biomedicines11061546", "PMC10295062", "37371642"]}, {"Citation": "Adamson Barnes N.S., Mitchell V.A., Kazantzis N.P., Vaughan C.W. Actions of the Dual FAAH/MAGL Inhibitor JZL195 in a Murine Neuropathic Pain Model. Br. J. Pharmacol. 2016;173:77\u201387. doi: 10.1111/bph.13337.", "ArticleIdList": ["10.1111/bph.13337", "PMC4813387", "26398331"]}, {"Citation": "Ahn K., Johnson D.S., Mileni M., Beidler D., Long J.Z., McKinney M.K., Weerapana E., Sadagopan N., Liimatta M., Smith S.E., et al. Discovery and Characterization of a Highly Selective FAAH Inhibitor That Reduces Inflammatory Pain. Chem. Biol. 2009;16:411\u2013420. doi: 10.1016/j.chembiol.2009.02.013.", "ArticleIdList": ["10.1016/j.chembiol.2009.02.013", "PMC2692831", "19389627"]}, {"Citation": "Kinsey S.G., Long J.Z., Cravatt B.F., Lichtman A.H. Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Inhibitors Produce Anti-Allodynic Effects in Mice through Distinct Cannabinoid Receptor Mechanisms. J. Pain. 2010;11:1420\u20131428. doi: 10.1016/j.jpain.2010.04.001.", "ArticleIdList": ["10.1016/j.jpain.2010.04.001", "PMC2962430", "20554481"]}, {"Citation": "Ignatowska-Jankowska B.M., Ghosh S., Crowe M.S., Kinsey S.G., Niphakis M.J., Abdullah R.A., Tao Q., O\u2019Neal S.T., Walentiny D.M., Wiley J.L., et al. In Vivo Characterization of the Highly Selective Monoacylglycerol Lipase Inhibitor KML29: Antinociceptive Activity without Cannabimimetic Side Effects. Br. J. Pharmacol. 2014;171:1392\u20131407. doi: 10.1111/bph.12298.", "ArticleIdList": ["10.1111/bph.12298", "PMC3954480", "23848221"]}, {"Citation": "Kinsey S.G., Wise L.E., Ramesh D., Abdullah R., Selley D.E., Cravatt B.F., Lichtman A.H. Repeated Low-Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains Cannabinoid Receptor Type 1-Mediated Antinociceptive and Gastroprotective Effects. J. Pharmacol. Exp. Ther. 2013;345:492\u2013501. doi: 10.1124/jpet.112.201426.", "ArticleIdList": ["10.1124/jpet.112.201426", "PMC3657109", "23412396"]}, {"Citation": "Brown T.M., Brotchie J.M., Fitzjohn S.M. Cannabinoids Decrease Corticostriatal Synaptic Transmission via an Effect on Glutamate Uptake. J. Neurosci. 2003;23:11073\u201311077. doi: 10.1523/JNEUROSCI.23-35-11073.2003.", "ArticleIdList": ["10.1523/JNEUROSCI.23-35-11073.2003", "PMC6741038", "14657164"]}, {"Citation": "Pertwee R.G. Handbook of Experimental Pharmacology. Springer; Berlin/Heidelberg, Germany: 2005. Pharmacological Actions of Cannabinoids; pp. 1\u201351.", "ArticleIdList": ["10.1007/3-540-26573-2_1", "16596770"]}, {"Citation": "Huang J., Fan X., Jin X., Jo S., Zhang H.B., Fujita A., Bean B.P., Yan N. Cannabidiol Inhibits Nav Channels through Two Distinct Binding Sites. Nat. Commun. 2023;14:3613. doi: 10.1038/s41467-023-39307-6.", "ArticleIdList": ["10.1038/s41467-023-39307-6", "PMC10276812", "37330538"]}, {"Citation": "Zhang H.-X.B., Bean B.P. Cannabidiol Inhibition of Murine Primary Nociceptors: Tight Binding to Slow Inactivated States of Nav1.8 Channels. J. Neurosci. 2021;41:6371\u20136387. doi: 10.1523/JNEUROSCI.3216-20.2021.", "ArticleIdList": ["10.1523/JNEUROSCI.3216-20.2021", "PMC8318087", "34131037"]}, {"Citation": "Ghovanloo M.-R., Shuart N.G., Mezeyova J., Dean R.A., Ruben P.C., Goodchild S.J. Inhibitory Effects of Cannabidiol on Voltage-Dependent Sodium Currents. J. Biol. Chem. 2018;293:16546\u201316558. doi: 10.1074/jbc.RA118.004929.", "ArticleIdList": ["10.1074/jbc.RA118.004929", "PMC6204917", "30219789"]}, {"Citation": "Watkins A.R. Cannabinoid Interactions with Ion Channels and Receptors. Channels. 2019;13:162\u2013167. doi: 10.1080/19336950.2019.1615824.", "ArticleIdList": ["10.1080/19336950.2019.1615824", "PMC6527074", "31088312"]}, {"Citation": "Xue Y., Chidiac C., Herault Y., Gaveriaux-Ruff C. Pain Behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) Mutant Rodent Models. Neurosci. Lett. 2021;753:135844. doi: 10.1016/j.neulet.2021.135844.", "ArticleIdList": ["10.1016/j.neulet.2021.135844", "33775738"]}, {"Citation": "Harding E.K., Souza I.A., Gandini M.A., Gadotti V.M., Ali M.Y., Huang S., Antunes F.T.T., Trang T., Zamponi G.W. Differential Regulation of Cav 3.2 and Cav 2.2 Calcium Channels by CB1 Receptors and Cannabidiol. Br. J. Pharmacol. 2023;180:1616\u20131633. doi: 10.1111/bph.16035.", "ArticleIdList": ["10.1111/bph.16035", "36647671"]}, {"Citation": "De Petrocellis L., Nabissi M., Santoni G., Ligresti A. Actions and Regulation of Ionotropic Cannabinoid Receptors. Adv. Pharmacol. 2017;80:249\u2013289. doi: 10.1016/bs.apha.2017.04.001.", "ArticleIdList": ["10.1016/bs.apha.2017.04.001", "28826537"]}, {"Citation": "Bakas T., van Nieuwenhuijzen P.S., Devenish S.O., McGregor I.S., Arnold J.C., Chebib M. The Direct Actions of Cannabidiol and 2-Arachidonoyl Glycerol at GABAA Receptors. Pharmacol. Res. 2017;119:358\u2013370. doi: 10.1016/j.phrs.2017.02.022.", "ArticleIdList": ["10.1016/j.phrs.2017.02.022", "28249817"]}, {"Citation": "Kossakowski R., Schlicker E., Toczek M., Weresa J., Malinowska B. Cannabidiol Affects the Bezold-Jarisch Reflex via TRPV1 and 5-HT3 Receptors and Has Peripheral Sympathomimetic Effects in Spontaneously Hypertensive and Normotensive Rats. Front. Pharmacol. 2019;10:500. doi: 10.3389/fphar.2019.00500.", "ArticleIdList": ["10.3389/fphar.2019.00500", "PMC6538767", "31178718"]}, {"Citation": "Arora V., Li T., Kumari S., Wang S., Asgar J., Chung M.-K. Capsaicin-Induced Depolymerization of Axonal Microtubules Mediates Analgesia for Trigeminal Neuropathic Pain. Pain. 2022;163:1479\u20131488. doi: 10.1097/j.pain.0000000000002529.", "ArticleIdList": ["10.1097/j.pain.0000000000002529", "PMC9046530", "34724681"]}, {"Citation": "Wong G.Y., Gavva N.R. Therapeutic Potential of Vanilloid Receptor TRPV1 Agonists and Antagonists as Analgesics: Recent Advances and Setbacks. Brain Res. Rev. 2009;60:267\u2013277. doi: 10.1016/j.brainresrev.2008.12.006.", "ArticleIdList": ["10.1016/j.brainresrev.2008.12.006", "19150372"]}, {"Citation": "Xiong W., Cui T., Cheng K., Yang F., Chen S.-R., Willenbring D., Guan Y., Pan H.-L., Ren K., Xu Y., et al. Cannabinoids Suppress Inflammatory and Neuropathic Pain by Targeting A3 Glycine Receptors. J. Exp. Med. 2012;209:1121\u20131134. doi: 10.1084/jem.20120242.", "ArticleIdList": ["10.1084/jem.20120242", "PMC3371734", "22585736"]}, {"Citation": "Okine B.N., Gaspar J.C., Finn D.P. PPARs and Pain. Br. J. Pharmacol. 2019;176:1421\u20131442. doi: 10.1111/bph.14339.", "ArticleIdList": ["10.1111/bph.14339", "PMC6487555", "29679493"]}, {"Citation": "Starowicz K., Finn D.P. Cannabinoids and Pain: Sites and Mechanisms of Action. Adv. Pharmacol. 2017;80:437\u2013475. doi: 10.1016/bs.apha.2017.05.003.", "ArticleIdList": ["10.1016/bs.apha.2017.05.003", "28826543"]}, {"Citation": "Hind W.H., England T.J., O\u2019Sullivan S.E. Cannabidiol Protects an in Vitro Model of the Blood-Brain Barrier from Oxygen-Glucose Deprivation via PPAR\u03b3 and 5-HT1A Receptors. Br. J. Pharmacol. 2016;173:815\u2013825. doi: 10.1111/bph.13368.", "ArticleIdList": ["10.1111/bph.13368", "PMC4761095", "26497782"]}, {"Citation": "O\u2019Sullivan S.E. Cannabinoids Go Nuclear: Evidence for Activation of Peroxisome Proliferator-Activated Receptors. Br. J. Pharmacol. 2007;152:576\u2013582. doi: 10.1038/sj.bjp.0707423.", "ArticleIdList": ["10.1038/sj.bjp.0707423", "PMC2190029", "17704824"]}, {"Citation": "O\u2019Sullivan S.E. An Update on PPAR Activation by Cannabinoids. Br. J. Pharmacol. 2016;173:1899\u20131910. doi: 10.1111/bph.13497.", "ArticleIdList": ["10.1111/bph.13497", "PMC4882496", "27077495"]}, {"Citation": "Silva N.R., Gomes F.I.F., Lopes A.H.P., Cortez I.L., Dos Santos J.C., Silva C.E.A., Mechoulam R., Gomes F.V., Cunha T.M., Guimar\u00e3es F.S. The Cannabidiol Analog PECS-101 Prevents Chemotherapy-Induced Neuropathic Pain via PPAR\u03b3 Receptors. Neurotherapeutics. 2022;19:434\u2013449. doi: 10.1007/s13311-021-01164-w.", "ArticleIdList": ["10.1007/s13311-021-01164-w", "PMC9130439", "34904193"]}, {"Citation": "Pertwee R.G., Rock E.M., Guenther K., Limebeer C.L., Stevenson L.A., Haj C., Smoum R., Parker L.A., Mechoulam R. Cannabidiolic Acid Methyl Ester, a Stable Synthetic Analogue of Cannabidiolic Acid, Can Produce 5-HT1A Receptor-Mediated Suppression of Nausea and Anxiety in Rats. Br. J. Pharmacol. 2018;175:100\u2013112. doi: 10.1111/bph.14073.", "ArticleIdList": ["10.1111/bph.14073", "PMC5740240", "29057454"]}, {"Citation": "Jesus C.H.A., Redivo D.D.B., Gasparin A.T., Sotomaior B.B., de Carvalho M.C., Genaro K., Zuardi A.W., Hallak J.E.C., Crippa J.A., Zanoveli J.M., et al. Cannabidiol Attenuates Mechanical Allodynia in Streptozotocin-Induced Diabetic Rats via Serotonergic System Activation through 5-HT1A Receptors. Brain Res. 2019;1715:156\u2013164. doi: 10.1016/j.brainres.2019.03.014.", "ArticleIdList": ["10.1016/j.brainres.2019.03.014", "30898678"]}, {"Citation": "Ward S.J., McAllister S.D., Kawamura R., Murase R., Neelakantan H., Walker E.A. Cannabidiol Inhibits Paclitaxel-Induced Neuropathic Pain through 5-HT1A Receptors without Diminishing Nervous System Function or Chemotherapy Efficacy. Br. J. Pharmacol. 2014;171:636\u2013645. doi: 10.1111/bph.12439.", "ArticleIdList": ["10.1111/bph.12439", "PMC3969077", "24117398"]}, {"Citation": "Zhang J., Chen C. \u03949-THC and COX-2 Signaling. In: Preedy V.R., editor. Handbook of Cannabis and Related Pathologies. Academic Press; San Diego, CA, USA: 2017. pp. 729\u2013738."}, {"Citation": "Szczyrba S., Kozera G., Bieniaszewski L., Nyka W.M. Neuropatia Cukrzycowa\u2014Patogeneza, Rozpoznawanie, Zapobieganie, Leczenie. Forum Med. Rodz. 2010;4:339\u2013355."}, {"Citation": "Yang K., Wang Y., Li Y., Chen Y., Xing N., Lin H., Zhou P., Yu X. Progress in the Treatment of Diabetic Peripheral Neuropathy. Biomed. Pharmacother. 2022;148:112717. doi: 10.1016/j.biopha.2022.112717.", "ArticleIdList": ["10.1016/j.biopha.2022.112717", "35193039"]}, {"Citation": "Rosenberger D.C., Blechschmidt V., Timmerman H., Wolff A., Treede R.-D. Challenges of Neuropathic Pain: Focus on Diabetic Neuropathy. J. Neural Transm. 2020;127:589\u2013624. doi: 10.1007/s00702-020-02145-7.", "ArticleIdList": ["10.1007/s00702-020-02145-7", "PMC7148276", "32036431"]}, {"Citation": "Wallace M.S., Marcotte T.D., Umlauf A., Gouaux B., Atkinson J.H. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. J. Pain. 2015;16:616\u2013627. doi: 10.1016/j.jpain.2015.03.008.", "ArticleIdList": ["10.1016/j.jpain.2015.03.008", "PMC5152762", "25843054"]}, {"Citation": "Wallace M.S., Marcotte T.D., Atkinson J.H., Padovano H.T., Bonn-Miller M. A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy. J. Pain. 2020;21:1175\u20131186. doi: 10.1016/j.jpain.2020.03.003.", "ArticleIdList": ["10.1016/j.jpain.2020.03.003", "32565122"]}, {"Citation": "Bagher A.M. The Endocannabinoid System as a Therapeutic Target in Diabetic Peripheral Neuropathic Pain: A Review. J. Microsc. Ultrastruct. 2021;10:47\u201354. doi: 10.4103/jmau.jmau_97_20.", "ArticleIdList": ["10.4103/jmau.jmau_97_20", "PMC9272697", "35832317"]}, {"Citation": "Maffei M.E. Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies. Int. J. Mol. Sci. 2020;21:7877. doi: 10.3390/ijms21217877.", "ArticleIdList": ["10.3390/ijms21217877", "PMC7660651", "33114203"]}, {"Citation": "Scaturro D., Vitagliani F., Signa G., Tomasello S., Tumminelli L.G., Picelli A., Smania N., Letizia Mauro G. Neck Pain in Fibromyalgia: Treatment with Exercise and Mesotherapy. Biomedicines. 2023;11:892. doi: 10.3390/biomedicines11030892.", "ArticleIdList": ["10.3390/biomedicines11030892", "PMC10045341", "36979871"]}, {"Citation": "van de Donk T., Niesters M., Kowal M.A., Olofsen E., Dahan A., van Velzen M. An Experimental Randomized Study on the Analgesic Effects of Pharmaceutical-Grade Cannabis in Chronic Pain Patients with Fibromyalgia. Pain. 2019;160:860\u2013869. doi: 10.1097/j.pain.0000000000001464.", "ArticleIdList": ["10.1097/j.pain.0000000000001464", "PMC6430597", "30585986"]}, {"Citation": "Chaves C., Bittencourt P.C.T., Pelegrini A. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Pain Med. 2020;21:2212\u20132218. doi: 10.1093/pm/pnaa303.", "ArticleIdList": ["10.1093/pm/pnaa303", "PMC7593796", "33118602"]}, {"Citation": "Ware M.A., Fitzcharles M.-A., Joseph L., Shir Y. The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial. Anesth Analg. 2010;110:604\u2013610. doi: 10.1213/ANE.0b013e3181c76f70.", "ArticleIdList": ["10.1213/ANE.0b013e3181c76f70", "20007734"]}, {"Citation": "Anthony A.T., Rahmat S., Sangle P., Sandhu O., Khan S., Anthony A.T., Rahmat S., Sangle P., Sandhu O., Khan S. Cannabinoid Receptors and Their Relationship with Chronic Pain: A Narrative Review. Cureus. 2020;12:e10436. doi: 10.7759/cureus.10436.", "ArticleIdList": ["10.7759/cureus.10436", "PMC7557112", "33072446"]}, {"Citation": "Walitt B., Klose P., Fitzcharles M.-A., Phillips T., H\u00e4user W. Cannabinoids for Fibromyalgia. Cochrane Database Syst. Rev. 2016:1\u201326. doi: 10.1002/14651858.CD011694.pub2.", "ArticleIdList": ["10.1002/14651858.CD011694.pub2", "PMC6457965", "27428009"]}, {"Citation": "Safakish R., Ko G., Salimpour V., Hendin B., Sohanpal I., Loheswaran G., Yoon S.Y.R. Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study. Pain Med. 2020;21:3073\u20133086. doi: 10.1093/pm/pnaa163.", "ArticleIdList": ["10.1093/pm/pnaa163", "32556203"]}, {"Citation": "Liu C., Ma H., Slitt A.L., Seeram N.P. Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes. J. Nat. Prod. 2020;83:2025\u20132029. doi: 10.1021/acs.jnatprod.0c00138.", "ArticleIdList": ["10.1021/acs.jnatprod.0c00138", "32374168"]}, {"Citation": "Libro R., Scionti D., Diomede F., Marchisio M., Grassi G., Pollastro F., Piattelli A., Bramanti P., Mazzon E., Trubiani O. Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front. Physiol. 2016;7:559. doi: 10.3389/fphys.2016.00559.", "ArticleIdList": ["10.3389/fphys.2016.00559", "PMC5121123", "27932991"]}, {"Citation": "Hask\u00f3 G., Cronstein B.N. Adenosine: An Endogenous Regulator of Innate Immunity. Trends Immunol. 2004;25:33\u201339. doi: 10.1016/j.it.2003.11.003.", "ArticleIdList": ["10.1016/j.it.2003.11.003", "14698282"]}, {"Citation": "Gambeta E., Chichorro J.G., Zamponi G.W. Trigeminal Neuralgia: An Overview from Pathophysiology to Pharmacological Treatments. Mol. Pain. 2020;16:1744806920901890. doi: 10.1177/1744806920901890.", "ArticleIdList": ["10.1177/1744806920901890", "PMC6985973", "31908187"]}, {"Citation": "Peciu-Florianu I., R\u00e9gis J., Levivier M., Dedeciusova M., Reyns N., Tuleasca C. Trigeminal Neuralgia Secondary to Meningiomas and Vestibular Schwannoma Is Improved after Stereotactic Radiosurgery: A Systematic Review and Meta-Analysis. Stereotact. Funct. Neurosurg. 2021;99:6\u201316. doi: 10.1159/000509842.", "ArticleIdList": ["10.1159/000509842", "32906130"]}, {"Citation": "Lee C.-H., Jang H.-Y., Won H.-S., Kim J.-S., Kim Y.-D. Epidemiology of Trigeminal Neuralgia: An Electronic Population Health Data Study in Korea. Korean J. Pain. 2021;34:332\u2013338. doi: 10.3344/kjp.2021.34.3.332.", "ArticleIdList": ["10.3344/kjp.2021.34.3.332", "PMC8255158", "34193639"]}, {"Citation": "Mechtler L., Hart P., Bargnes V., Saikali N. Medical Cannabis Treatment in Patients with Trigeminal Neuralgia (P5.10-020) Neurology. 2019;92:5\u201310. doi: 10.1212/WNL.92.15_supplement.P5.10-020.", "ArticleIdList": ["10.1212/WNL.92.15_supplement.P5.10-020"]}, {"Citation": "Hill A.J., Weston S.E., Jones N.A., Smith I., Bevan S.A., Williamson E.M., Stephens G.J., Williams C.M., Whalley B.J. \u03949-Tetrahydrocannabivarin Suppresses in Vitro Epileptiform and in Vivo Seizure Activity in Adult Rats. Epilepsia. 2010;51:1522\u20131532. doi: 10.1111/j.1528-1167.2010.02523.x.", "ArticleIdList": ["10.1111/j.1528-1167.2010.02523.x", "20196794"]}, {"Citation": "Garc\u00eda C., Palomo-Garo C., Garc\u00eda-Arencibia M., Ramos J., Pertwee R., Fern\u00e1ndez-Ruiz J. Symptom-Relieving and Neuroprotective Effects of the Phytocannabinoid \u03949-THCV in Animal Models of Parkinson\u2019s Disease. Br. J. Pharmacol. 2011;163:1495\u20131506. doi: 10.1111/j.1476-5381.2011.01278.x.", "ArticleIdList": ["10.1111/j.1476-5381.2011.01278.x", "PMC3165958", "21323909"]}, {"Citation": "Espadas I., Keifman E., Palomo-Garo C., Burgaz S., Garc\u00eda C., Fern\u00e1ndez-Ruiz J., Moratalla R. Beneficial Effects of the Phytocannabinoid \u03949-THCV in L-DOPA-Induced Dyskinesia in Parkinson\u2019s Disease. Neurobiol. Dis. 2020;141:104892. doi: 10.1016/j.nbd.2020.104892.", "ArticleIdList": ["10.1016/j.nbd.2020.104892", "32387338"]}, {"Citation": "Cascio M.G., Zamberletti E., Marini P., Parolaro D., Pertwee R.G. The Phytocannabinoid, \u03949-Tetrahydrocannabivarin, Can Act through 5-HT1A Receptors to Produce Antipsychotic Effects. Br. J. Pharmacol. 2015;172:1305\u20131318. doi: 10.1111/bph.13000.", "ArticleIdList": ["10.1111/bph.13000", "PMC4337703", "25363799"]}, {"Citation": "Hill A.J., Jones N.A., Smith I., Hill C.L., Williams C.M., Stephens G.J., Whalley B.J. Voltage-Gated Sodium (NaV) Channel Blockade by Plant Cannabinoids Does Not Confer Anticonvulsant Effects per Se. Neurosci. Lett. 2014;566:269\u2013274. doi: 10.1016/j.neulet.2014.03.013.", "ArticleIdList": ["10.1016/j.neulet.2014.03.013", "24642454"]}, {"Citation": "Mammana S., Cavalli E., Gugliandolo A., Silvestro S., Pollastro F., Bramanti P., Mazzon E. Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol. Medicina. 2019;55:747. doi: 10.3390/medicina55110747.", "ArticleIdList": ["10.3390/medicina55110747", "PMC6915685", "31752240"]}, {"Citation": "Fleisher-Berkovich S., Ventura Y., Amoyal M., Dahan A., Feinshtein V., Alfahel L., Israelson A., Bernstein N., Gorelick J., Ben-Shabat S. Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo. Biomolecules. 2023;13:376. doi: 10.3390/biom13020376.", "ArticleIdList": ["10.3390/biom13020376", "PMC9953076", "36830745"]}, {"Citation": "Granja A.G., Carrillo-Salinas F., Pagani A., G\u00f3mez-Ca\u00f1as M., Negri R., Navarrete C., Mecha M., Mestre L., Fiebich B.L., Cantarero I., et al. A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis. J. Neuroimmune Pharmacol. 2012;7:1002\u20131016. doi: 10.1007/s11481-012-9399-3.", "ArticleIdList": ["10.1007/s11481-012-9399-3", "22971837"]}, {"Citation": "Rodr\u00edguez-Cueto C., Santos-Garc\u00eda I., Garc\u00eda-Toscano L., Espejo-Porras F., Bellido M., Fern\u00e1ndez-Ruiz J., Mu\u00f1oz E., de Lago E. Neuroprotective Effects of the Cannabigerol Quinone Derivative VCE-003.2 in SOD1G93A Transgenic Mice, an Experimental Model of Amyotrophic Lateral Sclerosis. Biochem. Pharmacol. 2018;157:217\u2013226. doi: 10.1016/j.bcp.2018.07.049.", "ArticleIdList": ["10.1016/j.bcp.2018.07.049", "30076846"]}, {"Citation": "D\u00edaz-Alonso J., Para\u00edso-Luna J., Navarrete C., Del R\u00edo C., Cantarero I., Palomares B., Aguareles J., Fern\u00e1ndez-Ruiz J., Bellido M.L., Pollastro F., et al. VCE-003.2, a Novel Cannabigerol Derivative, Enhances Neuronal Progenitor Cell Survival and Alleviates Symptomatology in Murine Models of Huntington\u2019s Disease. Sci. Rep. 2016;6:29789. doi: 10.1038/srep29789.", "ArticleIdList": ["10.1038/srep29789", "PMC4949444", "27430371"]}, {"Citation": "Rodr\u00edguez-Carreiro S., Navarro E., Mu\u00f1oz E., Fern\u00e1ndez-Ruiz J. The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy. Brain Sci. 2023;13:1272. doi: 10.3390/brainsci13091272.", "ArticleIdList": ["10.3390/brainsci13091272", "PMC10527302", "37759872"]}, {"Citation": "Burgaz S., Garc\u00eda C., G\u00f3mez-Ca\u00f1as M., Mu\u00f1oz E., Fern\u00e1ndez-Ruiz J. Development of An Oral Treatment with the PPAR-\u03b3-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson\u2019s Disease. Molecules. 2019;24:2702. doi: 10.3390/molecules24152702.", "ArticleIdList": ["10.3390/molecules24152702", "PMC6696432", "31349553"]}, {"Citation": "Garc\u00eda C., G\u00f3mez-Ca\u00f1as M., Burgaz S., Palomares B., G\u00f3mez-G\u00e1lvez Y., Palomo-Garo C., Campo S., Ferrer-Hern\u00e1ndez J., Pavicic C., Navarrete C., et al. Benefits of VCE-003.2, a Cannabigerol Quinone Derivative, against Inflammation-Driven Neuronal Deterioration in Experimental Parkinson\u2019s Disease: Possible Involvement of Different Binding Sites at the PPAR\u03b3 Receptor. J. Neuroinflamm. 2018;15:19. doi: 10.1186/s12974-018-1060-5.", "ArticleIdList": ["10.1186/s12974-018-1060-5", "PMC5771072", "29338785"]}, {"Citation": "Shinjyo N., Di Marzo V. The Effect of Cannabichromene on Adult Neural Stem/Progenitor Cells. Neurochem. Int. 2013;63:432\u2013437. doi: 10.1016/j.neuint.2013.08.002.", "ArticleIdList": ["10.1016/j.neuint.2013.08.002", "23941747"]}, {"Citation": "Valeri A., Chiricosta L., D\u2019Angiolini S., Pollastro F., Salamone S., Mazzon E. Cannabichromene Induces Neuronal Differentiation in NSC-34 Cells: Insights from Transcriptomic Analysis. Life. 2023;13:742. doi: 10.3390/life13030742.", "ArticleIdList": ["10.3390/life13030742", "PMC10051538", "36983897"]}, {"Citation": "Raup-Konsavage W.M., Sepulveda D.E., Wang J., Dokholyan N.V., Vrana K.E., Graziane N.M. Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests. Biomedicines. 2023;12:83. doi: 10.3390/biomedicines12010083.", "ArticleIdList": ["10.3390/biomedicines12010083", "PMC10813533", "38255191"]}, {"Citation": "Hong M., Kim J.-H., Han J.-H., Ryu B.-R., Lim Y.-S., Lim J.-D., Park S.-H., Kim C.-H., Lee S.-U., Kwon T.-H. In Vitro and In Vivo Anti-Inflammatory Potential of Cannabichromene Isolated from Hemp. Plants. 2023;12:3966. doi: 10.3390/plants12233966.", "ArticleIdList": ["10.3390/plants12233966", "PMC10708362", "38068603"]}, {"Citation": "Thornton C., Dickson K.E., Carty D.R., Ashpole N.M., Willett K.L. Cannabis Constituents Reduce Seizure Behavior in Chemically-Induced and Scn1a-Mutant Zebrafish. Epilepsy Behav. 2020;110:107152. doi: 10.1016/j.yebeh.2020.107152.", "ArticleIdList": ["10.1016/j.yebeh.2020.107152", "PMC8276876", "32585475"]}, {"Citation": "Bourque J., Potvin S. Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs. Front. Psychiatry. 2021;12:596601. doi: 10.3389/fpsyt.2021.596601.", "ArticleIdList": ["10.3389/fpsyt.2021.596601", "PMC8222623", "34177633"]}, {"Citation": "Mueller R.L., Ellingson J.M., Bidwell L.C., Bryan A.D., Hutchison K.E. Are the Acute Effects of THC Different in Aging Adults? Brain Sci. 2021;11:590. doi: 10.3390/brainsci11050590.", "ArticleIdList": ["10.3390/brainsci11050590", "PMC8147270", "34062795"]}, {"Citation": "Hasbi A., Madras B.K., George S.R. Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. Brain Sci. 2023;13:325. doi: 10.3390/brainsci13020325.", "ArticleIdList": ["10.3390/brainsci13020325", "PMC9953886", "36831868"]}, {"Citation": "Bialas P., Fitzcharles M.-A., Klose P., H\u00e4user W. Long-Term Observational Studies with Cannabis-Based Medicines for Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis of Effectiveness and Safety. Eur. J. Pain. 2022;26:1221\u20131233. doi: 10.1002/ejp.1957.", "ArticleIdList": ["10.1002/ejp.1957", "35467781"]}, {"Citation": "Alessandria G., Meli R., Infante M.T., Vestito L., Capello E., Bandini F. Long-Term Assessment of the Cognitive Effects of Nabiximols in Patients with Multiple Sclerosis: A Pilot Study. Clin. Neurol. Neurosurg. 2020;196:105990. doi: 10.1016/j.clineuro.2020.105990.", "ArticleIdList": ["10.1016/j.clineuro.2020.105990", "32526487"]}, {"Citation": "Iversen L. Cannabis and the Brain. Brain. 2003;126:1252\u20131270. doi: 10.1093/brain/awg143.", "ArticleIdList": ["10.1093/brain/awg143", "12764049"]}, {"Citation": "Ronan P.J., Wongngamnit N., Beresford T.P. Molecular Mechanisms of Cannabis Signaling in the Brain. In: Rahman S., editor. Progress in Molecular Biology and Translational Science. Volume 137. Academic Press; Cambridge, MA, USA: 2016. pp. 123\u2013147. The Molecular Basis of Drug Addiction.", "ArticleIdList": ["26810000"]}, {"Citation": "Rabino M., Mallia S., Castiglioni E., Rovina D., Pompilio G., Gowran A. The Endocannabinoid System and Cannabidiol: Past, Present, and Prospective for Cardiovascular Diseases. Pharmaceuticals. 2021;14:936. doi: 10.3390/ph14090936.", "ArticleIdList": ["10.3390/ph14090936", "PMC8472406", "34577636"]}, {"Citation": "Kilaru A., Chapman K.D. The Endocannabinoid System. Essays Biochem. 2020;64:485\u2013499. doi: 10.1042/EBC20190086.", "ArticleIdList": ["10.1042/EBC20190086", "32648908"]}, {"Citation": "Batalla A., Bos J., Postma A., Bossong M.G. The Impact of Cannabidiol on Human Brain Function: A Systematic Review. Front. Pharmacol. 2021;11:618184. doi: 10.3389/fphar.2020.618184.", "ArticleIdList": ["10.3389/fphar.2020.618184", "PMC7858248", "33551817"]}, {"Citation": "Cohen K., Weizman A., Weinstein A. Modulatory Effects of Cannabinoids on Brain Neurotransmission. Eur. J. Neurosci. 2019;50:2322\u20132345. doi: 10.1111/ejn.14407.", "ArticleIdList": ["10.1111/ejn.14407", "30882962"]}, {"Citation": "Adel Y., Alexander S.P.H. Neuromolecular Mechanisms of Cannabis Action. Adv. Exp. Med. Biol. 2021;1264:15\u201328. doi: 10.1007/978-3-030-57369-0_2.", "ArticleIdList": ["10.1007/978-3-030-57369-0_2", "33332001"]}, {"Citation": "Kitdumrongthum S., Trachootham D. An Individuality of Response to Cannabinoids: Challenges in Safety and Efficacy of Cannabis Products. Molecules. 2023;28:2791. doi: 10.3390/molecules28062791.", "ArticleIdList": ["10.3390/molecules28062791", "PMC10058560", "36985763"]}, {"Citation": "Babayeva M., Loewy Z.G. Cannabis Pharmacogenomics: A Path to Personalized Medicine. Curr. Issues Mol. Biol. 2023;45:3479\u20133514. doi: 10.3390/cimb45040228.", "ArticleIdList": ["10.3390/cimb45040228", "PMC10137111", "37185752"]}, {"Citation": "Cooper Z.D., Craft R.M. Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. Neuropsychopharmacology. 2018;43:34\u201351. doi: 10.1038/npp.2017.140.", "ArticleIdList": ["10.1038/npp.2017.140", "PMC5719093", "28811670"]}, {"Citation": "Arkell T.R., Kevin R.C., Vinckenbosch F., Lintzeris N., Theunissen E., Ramaekers J.G., McGregor I.S. Sex Differences in Acute Cannabis Effects Revisited: Results from Two Randomized, Controlled Trials. Addict. Biol. 2022;27:e13125. doi: 10.1111/adb.13125.", "ArticleIdList": ["10.1111/adb.13125", "PMC9286641", "34936167"]}, {"Citation": "Zamberletti E., Rubino T. Dos(e)Age: Role of Dose and Age in the Long-Term Effect of Cannabinoids on Cognition. Molecules. 2022;27:1411. doi: 10.3390/molecules27041411.", "ArticleIdList": ["10.3390/molecules27041411", "PMC8876668", "35209200"]}, {"Citation": "O\u2019Brien K., Blair P. Routes of Administration, Pharmacokinetics and Safety of Medicinal Cannabis. In: O\u2019Brien K., Blair P., editors. Medicinal Cannabis and CBD in Mental Healthcare. Springer International Publishing; Cham, Switzerland: 2021. pp. 513\u2013557."}, {"Citation": "McGilveray I.J. Pharmacokinetics of Cannabinoids. Pain Res. Manag. 2005;10((Suppl. SA)):15A\u201322A. doi: 10.1155/2005/242516.", "ArticleIdList": ["10.1155/2005/242516", "16237477"]}, {"Citation": "Lucas C.J., Galettis P., Schneider J. The Pharmacokinetics and the Pharmacodynamics of Cannabinoids. Br. J. Clin. Pharmacol. 2018;84:2477\u20132482. doi: 10.1111/bcp.13710.", "ArticleIdList": ["10.1111/bcp.13710", "PMC6177698", "30001569"]}, {"Citation": "Bell A.D., MacCallum C., Margolese S., Walsh Z., Wright P., Daeninck P.J., Mandarino E., Lacasse G., Kaur Deol J., de Freitas L., et al. Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. Cannabis Cannabinoid Res. 2024;9:669\u2013687. doi: 10.1089/can.2021.0156.", "ArticleIdList": ["10.1089/can.2021.0156", "PMC10998028", "36971587"]}, {"Citation": "Hordowicz M., Jarosz J., Czapli\u0144ska M., Leonhard A., Klimkiewicz A. Polish Physicians\u2019 Perspectives on Medical Cannabis Policy and Educational Needs: Results of An Online Survey. J. Clin. Med. 2021;10:4545. doi: 10.3390/jcm10194545.", "ArticleIdList": ["10.3390/jcm10194545", "PMC8509273", "34640561"]}, {"Citation": "Kruger D.J., Mokbel M.A., Clauw D.J., Boehnke K.F. Assessing Health Care Providers\u2019 Knowledge of Medical Cannabis. Cannabis Cannabinoid Res. 2022;7:501\u2013507. doi: 10.1089/can.2021.0032.", "ArticleIdList": ["10.1089/can.2021.0032", "PMC9418358", "34463161"]}, {"Citation": "St Pierre M., Matthews L., Walsh Z. Cannabis Education Needs Assessment among Canadian Physicians-in-Training. Complement. Ther. Med. 2020;49:102328. doi: 10.1016/j.ctim.2020.102328.", "ArticleIdList": ["10.1016/j.ctim.2020.102328", "32147035"]}, {"Citation": "Philpot L.M., Ebbert J.O., Hurt R.T. A Survey of the Attitudes, Beliefs and Knowledge about Medical Cannabis among Primary Care Providers. BMC Fam. Pract. 2019;20:17. doi: 10.1186/s12875-019-0906-y.", "ArticleIdList": ["10.1186/s12875-019-0906-y", "PMC6341534", "30669979"]}, {"Citation": "Jankie S., Sewdass K., Smith W., Naraynsingh C., Johnson J., Farnon N., Mahadeo K., Motilal S. A Cross-Sectional Survey of Prospective Healthcare Professionals\u2019 Knowledge, Attitudes and Perceptions of Medical Cannabis. Explor. Res. Clin. Soc. Pharm. 2023;10:100275. doi: 10.1016/j.rcsop.2023.100275.", "ArticleIdList": ["10.1016/j.rcsop.2023.100275", "PMC10165452", "37168830"]}]}], "History": [{"Year": "2024", "Month": "3", "Day": "12"}, {"Year": "2024", "Month": "5", "Day": "20"}, {"Year": "2024", "Month": "5", "Day": "23"}, {"Year": "2024", "Month": "6", "Day": "19", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "6", "Day": "19", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "6", "Day": "19", "Hour": "1", "Minute": "7"}, {"Year": "2024", "Month": "5", "Day": "25"}], "PublicationStatus": "epublish", "ArticleIdList": ["38891938", "PMC11171823", "10.3390/ijms25115749", "ijms25115749"]}}]}